---
title: "Blog & Learning Hub | PepTracker Pro"
description: "Educational articles about peptides, research summaries, myth-busting, and glossary deep-dives."
lang: en
json-ld:
---

[Skip to main content](#main)

**Educational information only.** This site does not provide medical advice. [Read full disclaimer](/disclaimer) 

[PepTracker Pro](/)

[Home](/)[Peptides](/peptides)[Compare](/compare)[Glossary](/glossary)[Blog](/blog)[Calculators](/calculators)[Start Here](/start)

[Open the App](https://app.peptrackerpro.com)

# Blog & Learning Hub

Educational peptide content backed by research citations.

Research & Compounds 

## [Trontinemab and the Brainshuttle Bet: Roche's Anti-Amyloid Antibody That Sneaks Into the Brain (August 25, 2026)](/blog/trontinemab-roche-genentech-rg6102-ro7126209-brainshuttle-transferrin-receptor-tfr1-anti-amyloid-beta-gantenerumab-bispecific-antibody-alzheimers-disease-aria-centiloid-brainshuttle-ad-trontier-1-trontier-2-preventron-p-tau217-august-25-2026)

Antibodies barely cross into the brain - which is why anti-amyloid Alzheimer's drugs need big infusions and still cause brain swelling. Roche's trontinemab flips the problem: it hitches a plaque-clearing antibody to a transferrin-receptor 'shuttle' that ferries it across the blood-brain barrier. Early data show some of the fastest, deepest amyloid clearance yet - with strikingly little ARIA. Here's what trontinemab is, how the Brainshuttle works, and why TRONTIER 1/2 and the new PrevenTRON prevention trial are the readouts to watch.

[Read article →](/blog/trontinemab-roche-genentech-rg6102-ro7126209-brainshuttle-transferrin-receptor-tfr1-anti-amyloid-beta-gantenerumab-bispecific-antibody-alzheimers-disease-aria-centiloid-brainshuttle-ad-trontier-1-trontier-2-preventron-p-tau217-august-25-2026)

Peptide GuidesResearch SummariesMyth vs FactGlossary Highlights

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/trontinemab-roche-genentech-rg6102-ro7126209-brainshuttle-transferrin-receptor-tfr1-anti-amyloid-beta-gantenerumab-bispecific-antibody-alzheimers-disease-aria-centiloid-brainshuttle-ad-trontier-1-trontier-2-preventron-p-tau217-august-25-2026)

Research & Compounds [

### Trontinemab and the Brainshuttle Bet: Roche's Anti-Amyloid Antibody That Sneaks Into the Brain (August 25, 2026)

](/blog/trontinemab-roche-genentech-rg6102-ro7126209-brainshuttle-transferrin-receptor-tfr1-anti-amyloid-beta-gantenerumab-bispecific-antibody-alzheimers-disease-aria-centiloid-brainshuttle-ad-trontier-1-trontier-2-preventron-p-tau217-august-25-2026)

Antibodies barely cross into the brain - which is why anti-amyloid Alzheimer's drugs need big infusions and still cause brain swelling. Roche's trontinemab flips the problem: it hitches a plaque-clearing antibody to a transferrin-receptor 'shuttle' that ferries it across the blood-brain barrier. Early data show some of the fastest, deepest amyloid clearance yet - with strikingly little ARIA. Here's what trontinemab is, how the Brainshuttle works, and why TRONTIER 1/2 and the new PrevenTRON prevention trial are the readouts to watch.

PepTracker Pro Team 

August 25, 2026  8 min read 

trontinemabRG6102RO7126209

[Read](/blog/trontinemab-roche-genentech-rg6102-ro7126209-brainshuttle-transferrin-receptor-tfr1-anti-amyloid-beta-gantenerumab-bispecific-antibody-alzheimers-disease-aria-centiloid-brainshuttle-ad-trontier-1-trontier-2-preventron-p-tau217-august-25-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/ziltivekimab-novo-nordisk-corvidia-il-6-interleukin-6-monoclonal-antibody-anti-inflammatory-residual-inflammatory-risk-hscrp-crp-cantos-canakinumab-rescue-zeus-hermes-artemis-ascvd-ckd-cardiovascular-outcomes-mace-august-24-2026)

Research & Compounds [

### Ziltivekimab and the ZEUS Miss: When Crushing Inflammation Didn't Save the Heart (August 24, 2026)

](/blog/ziltivekimab-novo-nordisk-corvidia-il-6-interleukin-6-monoclonal-antibody-anti-inflammatory-residual-inflammatory-risk-hscrp-crp-cantos-canakinumab-rescue-zeus-hermes-artemis-ascvd-ckd-cardiovascular-outcomes-mace-august-24-2026)

For years, cardiology chased a tantalizing idea: that quieting inflammation - not just lowering cholesterol - could prevent heart attacks. Ziltivekimab, Novo Nordisk's once-monthly anti-IL-6 antibody, was built to prove it. In July 2026 the pivotal ZEUS trial delivered a hard answer: the drug crushed inflammatory markers but did not cut cardiovascular events. Here's what ziltivekimab is, why it mattered, and what the surprising 'engagement-without-benefit' result means.

PepTracker Pro Team 

August 24, 2026  8 min read 

ziltivekimabNovo NordiskCorvidia

[Read](/blog/ziltivekimab-novo-nordisk-corvidia-il-6-interleukin-6-monoclonal-antibody-anti-inflammatory-residual-inflammatory-risk-hscrp-crp-cantos-canakinumab-rescue-zeus-hermes-artemis-ascvd-ckd-cardiovascular-outcomes-mace-august-24-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/eplontersen-wainua-wainzua-ionis-astrazeneca-ttr-transthyretin-galnac-antisense-oligonucleotide-aso-attr-amyloidosis-polyneuropathy-cardiomyopathy-attr-cm-neuro-ttransform-cardio-ttransform-missed-endpoint-monotherapy-august-23-2026)

Research & Compounds [

### Eplontersen (Wainua): The Antisense TTR Silencer That Missed in the Heart - What CARDIO-TTRansform Means Next to Vutrisiran's Success (August 23, 2026)

](/blog/eplontersen-wainua-wainzua-ionis-astrazeneca-ttr-transthyretin-galnac-antisense-oligonucleotide-aso-attr-amyloidosis-polyneuropathy-cardiomyopathy-attr-cm-neuro-ttransform-cardio-ttransform-missed-endpoint-monotherapy-august-23-2026)

Vutrisiran silenced TTR and moved mortality. Eplontersen silences the same protein a different way - as an antisense oligonucleotide - and in July 2026 its huge ATTR cardiomyopathy trial, CARDIO-TTRansform, missed its primary endpoint. Here is how Ionis and AstraZeneca's once-monthly Wainua works, why it succeeded in nerves but stumbled in the heart, and what the monotherapy signal tells us about adding a silencer on top of tafamidis.

PepTracker Pro Team 

August 23, 2026  8 min read 

eplontersenWainuaWainzua

[Read](/blog/eplontersen-wainua-wainzua-ionis-astrazeneca-ttr-transthyretin-galnac-antisense-oligonucleotide-aso-attr-amyloidosis-polyneuropathy-cardiomyopathy-attr-cm-neuro-ttransform-cardio-ttransform-missed-endpoint-monotherapy-august-23-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/vutrisiran-amvuttra-alnylam-ttr-transthyretin-galnac-sirna-rnai-attr-amyloidosis-cardiomyopathy-attr-cm-helios-a-helios-b-cardiovascular-outcomes-quarterly-august-19-2026)

Research & Compounds [

### Vutrisiran (Amvuttra): The First RNAi Drug Proven to Cut Cardiovascular Death - How Alnylam's Quarterly TTR-Silencing Injection Treats ATTR Amyloidosis and What HELIOS-B Showed (August 19, 2026)

](/blog/vutrisiran-amvuttra-alnylam-ttr-transthyretin-galnac-sirna-rnai-attr-amyloidosis-cardiomyopathy-attr-cm-helios-a-helios-b-cardiovascular-outcomes-quarterly-august-19-2026)

Most gene-silencing drugs move a lab value. Vutrisiran moved mortality. Alnylam's quarterly subcutaneous injection silences the TTR gene in the liver to treat ATTR amyloidosis, and in the HELIOS-B trial it became the first RNAi therapeutic proven to reduce cardiovascular death and events in ATTR cardiomyopathy. Here is how it works, from GalNAc chemistry to the heart data that earned its 2025 label.

PepTracker Pro Team 

August 19, 2026  8 min read 

vutrisiranAmvuttraAlnylam

[Read](/blog/vutrisiran-amvuttra-alnylam-ttr-transthyretin-galnac-sirna-rnai-attr-amyloidosis-cardiomyopathy-attr-cm-helios-a-helios-b-cardiovascular-outcomes-quarterly-august-19-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/efpeglenatide-hanmi-exendin-4-glp1-receptor-agonist-lapscovery-amplitude-o-cardiovascular-kidney-outcomes-obesity-once-weekly-sanofi-august-18-2026)

Research & Compounds [

### Efpeglenatide: The Gila-Monster-Derived, Once-Weekly GLP-1 With Landmark Heart and Kidney Data - How Hanmi's Exendin-Fc Injection Works and Where It Stands in 2026 (August 18, 2026)

](/blog/efpeglenatide-hanmi-exendin-4-glp1-receptor-agonist-lapscovery-amplitude-o-cardiovascular-kidney-outcomes-obesity-once-weekly-sanofi-august-18-2026)

Most GLP-1 drugs are built from human GLP-1. Efpeglenatide starts somewhere stranger - exendin-4, a peptide from Gila monster venom - and bolts it to an antibody fragment so one injection lasts a week. It is the GLP-1 that produced one of the clearest kidney signals in the class in the AMPLITUDE-O trial, and after a detour through Sanofi it is now heading toward a 2026 obesity launch in South Korea. Here is how it works and where the data actually stand.

PepTracker Pro Team 

August 18, 2026  8 min read 

efpeglenatideHanmiexendin-4

[Read](/blog/efpeglenatide-hanmi-exendin-4-glp1-receptor-agonist-lapscovery-amplitude-o-cardiovascular-kidney-outcomes-obesity-once-weekly-sanofi-august-18-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/inclisiran-leqvio-novartis-alnylam-pcsk9-galnac-sirna-rnai-ldl-cholesterol-twice-yearly-orion-9-orion-10-orion-11-victorion-2-prevent-cardiovascular-outcomes-monotherapy-august-17-2026)

Research & Compounds [

### Inclisiran (Leqvio): The Twice-a-Year siRNA Injection That Halves LDL Cholesterol - How PCSK9 Silencing Works and Where the Outcomes Data Stand (August 17, 2026)

](/blog/inclisiran-leqvio-novartis-alnylam-pcsk9-galnac-sirna-rnai-ldl-cholesterol-twice-yearly-orion-9-orion-10-orion-11-victorion-2-prevent-cardiovascular-outcomes-monotherapy-august-17-2026)

Statins and daily pills lose their power when patients stop taking them. Inclisiran (Leqvio) takes a different route: a subcutaneous injection given just twice a year that silences the liver protein PCSK9 and cuts LDL cholesterol by about half. It was the first RNA-interference medicine approved for a common chronic cardiovascular condition, and in 2025 the FDA broadened its label to first-line use. Here is how PCSK9 silencing works, what the ORION trials showed, how inclisiran compares with the PCSK9 antibodies, and why the VICTORION outcomes trials are the test that still matters.

PepTracker Pro Team 

August 17, 2026  8 min read 

inclisiranLeqvioALN-PCSsc

[Read](/blog/inclisiran-leqvio-novartis-alnylam-pcsk9-galnac-sirna-rnai-ldl-cholesterol-twice-yearly-orion-9-orion-10-orion-11-victorion-2-prevent-cardiovascular-outcomes-monotherapy-august-17-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/solbinsiran-lilly-ly3561774-angptl3-galnac-sirna-rnai-apob-triglycerides-ldl-remnant-cholesterol-mixed-dyslipidemia-prolong-ang3-phase-3-cardiovascular-outcomes-august-16-2026)

Research & Compounds [

### Solbinsiran: Lilly's ANGPTL3-Silencing RNAi Injection That Lowers LDL and Triglycerides Together - Inside the Phase 2 PROLONG-ANG3 Trial (August 16, 2026)

](/blog/solbinsiran-lilly-ly3561774-angptl3-galnac-sirna-rnai-apob-triglycerides-ldl-remnant-cholesterol-mixed-dyslipidemia-prolong-ang3-phase-3-cardiovascular-outcomes-august-16-2026)

Statins lower LDL, but many patients still carry risk from triglyceride-rich remnants. Solbinsiran, Lilly's investigational GalNAc-siRNA, silences the liver protein ANGPTL3 to cut LDL and triglycerides at the same time - with an injection given only a few times a year. Here is what the Phase 2 PROLONG-ANG3 trial showed, how solbinsiran compares with the other ANGPTL3 siRNA zodasiran, and why a Phase 3 cardiovascular outcomes trial is being built on the results.

PepTracker Pro Team 

August 16, 2026  8 min read 

solbinsiranLY3561774ANGPTL3

[Read](/blog/solbinsiran-lilly-ly3561774-angptl3-galnac-sirna-rnai-apob-triglycerides-ldl-remnant-cholesterol-mixed-dyslipidemia-prolong-ang3-phase-3-cardiovascular-outcomes-august-16-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/zodasiran-arrowhead-aro-ang3-angptl3-galnac-sirna-rnai-triglycerides-remnant-cholesterol-ldl-homozygous-familial-hypercholesterolemia-hofh-arches-2-gateway-yosemite-august-15-2026)

Research & Compounds [

### Zodasiran: The ANGPTL3-Silencing RNAi Injection That Lowers Triglycerides, Remnant Cholesterol and LDL - ARCHES-2, GATEWAY and the Phase 3 YOSEMITE Trial in Homozygous FH (August 15, 2026)

](/blog/zodasiran-arrowhead-aro-ang3-angptl3-galnac-sirna-rnai-triglycerides-remnant-cholesterol-ldl-homozygous-familial-hypercholesterolemia-hofh-arches-2-gateway-yosemite-august-15-2026)

Most cholesterol drugs work through the LDL receptor - but some patients barely have one. Zodasiran, Arrowhead's investigational GalNAc-siRNA, silences the liver protein ANGPTL3 to cut triglycerides, remnant cholesterol and LDL through an LDL-receptor-independent route. Here is what the Phase 2b ARCHES-2 trial and the Phase 2 GATEWAY study in homozygous familial hypercholesterolemia showed, and what the pivotal Phase 3 YOSEMITE trial - enrollment completed in July 2026 - is testing.

PepTracker Pro Team 

August 15, 2026  8 min read 

zodasiranARO-ANG3ANGPTL3

[Read](/blog/zodasiran-arrowhead-aro-ang3-angptl3-galnac-sirna-rnai-triglycerides-remnant-cholesterol-ldl-homozygous-familial-hypercholesterolemia-hofh-arches-2-gateway-yosemite-august-15-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/zilebesiran-alnylam-roche-genentech-angiotensinogen-agt-galnac-sirna-rnai-hypertension-blood-pressure-raas-kardia-1-kardia-2-kardia-3-zenith-cardiovascular-outcomes-august-14-2026)

Research & Compounds [

### Zilebesiran: The Twice-a-Year RNAi Shot That Silences Angiotensinogen to Lower Blood Pressure - KARDIA-1, KARDIA-2, KARDIA-3 and the Phase 3 ZENITH Outcomes Trial (August 14, 2026)

](/blog/zilebesiran-alnylam-roche-genentech-angiotensinogen-agt-galnac-sirna-rnai-hypertension-blood-pressure-raas-kardia-1-kardia-2-kardia-3-zenith-cardiovascular-outcomes-august-14-2026)

Most blood-pressure drugs must be taken every day, and most patients never reach goal. Zilebesiran takes a different route: a GalNAc-siRNA injection given as rarely as twice a year that silences angiotensinogen - the single upstream protein behind the entire renin-angiotensin system - and lowers systolic blood pressure for up to 6 months from one dose. Here is what KARDIA-1, KARDIA-2 and KARDIA-3 showed, and what the 11,000-patient Phase 3 ZENITH outcomes trial is testing.

PepTracker Pro Team 

August 14, 2026  8 min read 

zilebesiranALN-AGTangiotensinogen

[Read](/blog/zilebesiran-alnylam-roche-genentech-angiotensinogen-agt-galnac-sirna-rnai-hypertension-blood-pressure-raas-kardia-1-kardia-2-kardia-3-zenith-cardiovascular-outcomes-august-14-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/olezarsen-ionis-tryngolza-apoc3-apolipoprotein-c-iii-antisense-oligonucleotide-aso-triglycerides-familial-chylomicronemia-fcs-severe-hypertriglyceridemia-shtg-balance-core-core2-pancreatitis-august-13-2026)

Research & Compounds [

### Olezarsen (Tryngolza): The apoC-III Antisense Drug Now Approved for Severe Hypertriglyceridemia - BALANCE, CORE and CORE2 (August 13, 2026)

](/blog/olezarsen-ionis-tryngolza-apoc3-apolipoprotein-c-iii-antisense-oligonucleotide-aso-triglycerides-familial-chylomicronemia-fcs-severe-hypertriglyceridemia-shtg-balance-core-core2-pancreatitis-august-13-2026)

Extreme triglycerides can top 1,000 mg/dL and trigger life-threatening pancreatitis, and for decades there was almost nothing to offer. Olezarsen - a once-monthly antisense injection that silences apoC-III - became the first therapy ever approved for familial chylomicronemia syndrome in December 2024, and on June 24, 2026 it became the first and only treatment approved to cut triglycerides and acute pancreatitis risk in the far larger severe hypertriglyceridemia population. Here is how it works, what BALANCE, CORE and CORE2 showed, and how it compares with the siRNA rival plozasiran.

PepTracker Pro Team 

August 13, 2026  8 min read 

olezarsenTryngolzaISIS 678354

[Read](/blog/olezarsen-ionis-tryngolza-apoc3-apolipoprotein-c-iii-antisense-oligonucleotide-aso-triglycerides-familial-chylomicronemia-fcs-severe-hypertriglyceridemia-shtg-balance-core-core2-pancreatitis-august-13-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/plozasiran-arrowhead-redemplo-apoc3-apolipoprotein-c-iii-rnai-sirna-triglycerides-familial-chylomicronemia-fcs-palisade-shasta-pancreatitis-severe-hypertriglyceridemia-august-11-2026)

Research & Compounds [

### Plozasiran (Redemplo): The apoC-III Silencer That Cuts Triglycerides ~80% and Slashes Pancreatitis - PALISADE, SHASTA-3 and SHASTA-4 (August 11, 2026)

](/blog/plozasiran-arrowhead-redemplo-apoc3-apolipoprotein-c-iii-rnai-sirna-triglycerides-familial-chylomicronemia-fcs-palisade-shasta-pancreatitis-severe-hypertriglyceridemia-august-11-2026)

Extreme triglycerides can top 1,000 mg/dL and trigger life-threatening pancreatitis, and for decades there was almost nothing to offer. Plozasiran - an every-three-months RNAi injection that silences apoC-III - cut triglycerides by about 80% and sharply reduced pancreatitis events. It won FDA approval as Redemplo for familial chylomicronemia syndrome in November 2025, and July 2026 Phase 3 data now push it toward the far larger severe hypertriglyceridemia population.

PepTracker Pro Team 

August 11, 2026  8 min read 

plozasiranARO-APOC3Redemplo

[Read](/blog/plozasiran-arrowhead-redemplo-apoc3-apolipoprotein-c-iii-rnai-sirna-triglycerides-familial-chylomicronemia-fcs-palisade-shasta-pancreatitis-severe-hypertriglyceridemia-august-11-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/obicetrapib-newamsterdam-menarini-cetp-inhibitor-oral-ldl-lp-a-lipoprotein-a-apob-broadway-tandem-brooklyn-prevail-ubeslo-evlarco-ezetimibe-chmp-august-10-2026)

Research & Compounds [

### Obicetrapib: The Oral CETP Pill That Lowers Both LDL and Lp(a) - BROADWAY, TANDEM, and a CHMP Green Light (August 10, 2026)

](/blog/obicetrapib-newamsterdam-menarini-cetp-inhibitor-oral-ldl-lp-a-lipoprotein-a-apob-broadway-tandem-brooklyn-prevail-ubeslo-evlarco-ezetimibe-chmp-august-10-2026)

CETP inhibitors were left for dead after torcetrapib raised blood pressure and killed patients. Obicetrapib revived the class - not by raising HDL, but by lowering LDL cholesterol by about a third and lipoprotein(a) by ~33% in a single once-daily oral pill. Here's what the Phase 3 BROADWAY and TANDEM trials showed, why its July 2026 EMA CHMP green light matters, and how the PREVAIL outcomes trial will decide its fate.

PepTracker Pro Team 

August 10, 2026  7 min read 

obicetrapibTA-8995AMG 899

[Read](/blog/obicetrapib-newamsterdam-menarini-cetp-inhibitor-oral-ldl-lp-a-lipoprotein-a-apob-broadway-tandem-brooklyn-prevail-ubeslo-evlarco-ezetimibe-chmp-august-10-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/muvalaplin-lilly-kraken-oral-small-molecule-lp-a-lipoprotein-a-apolipoprotein-a-apob-formation-inhibitor-ly3473329-move-lp-a-cardiovascular-outcomes-august-9-2026)

Research & Compounds [

### Muvalaplin: The First Lp(a)-Lowering Pill — an Oral Drug That Cut Lipoprotein(a) by up to 86% (August 9, 2026)

](/blog/muvalaplin-lilly-kraken-oral-small-molecule-lp-a-lipoprotein-a-apolipoprotein-a-apob-formation-inhibitor-ly3473329-move-lp-a-cardiovascular-outcomes-august-9-2026)

About one in five people inherit high lipoprotein(a) — a genetic driver of heart attacks and strokes that statins and PCSK9 inhibitors can't touch, and that every advanced treatment so far has required an injection to lower. Muvalaplin, an oral small molecule from Eli Lilly, breaks that pattern: a once-daily pill that blocks Lp(a) from ever assembling, cutting it by up to 86% in the Phase 2 KRAKEN trial. Here's how it works, what KRAKEN showed, and why its Phase 3 MOVE-Lp(a) outcomes trial matters.

PepTracker Pro Team 

August 9, 2026  7 min read 

muvalaplinLY3473329lipoprotein(a)

[Read](/blog/muvalaplin-lilly-kraken-oral-small-molecule-lp-a-lipoprotein-a-apolipoprotein-a-apob-formation-inhibitor-ly3473329-move-lp-a-cardiovascular-outcomes-august-9-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/zerlasiran-silence-therapeutics-alpacar-360-sirna-lp-a-lipoprotein-a-apolipoprotein-a-sln360-galnac-gene-silencing-cardiovascular-partner-august-8-2026)

Research & Compounds [

### Zerlasiran: The Twice-a-Year siRNA That Cut Lp(a) by Over 80% — and Why Its Phase 3 Is Waiting (August 8, 2026)

](/blog/zerlasiran-silence-therapeutics-alpacar-360-sirna-lp-a-lipoprotein-a-apolipoprotein-a-sln360-galnac-gene-silencing-cardiovascular-partner-august-8-2026)

About one in five people inherit high lipoprotein(a) — a genetic driver of heart attacks and strokes that statins and PCSK9 inhibitors can't touch. Zerlasiran, a long-acting siRNA from Silence Therapeutics, cut Lp(a) by more than 80% with dosing as infrequent as every 16–24 weeks. Here's how it works, what its Phase 2 ALPACAR-360 trial showed, and why its Phase 3 is on hold.

PepTracker Pro Team 

August 8, 2026  7 min read 

zerlasiranSLN360lipoprotein(a)

[Read](/blog/zerlasiran-silence-therapeutics-alpacar-360-sirna-lp-a-lipoprotein-a-apolipoprotein-a-sln360-galnac-gene-silencing-cardiovascular-partner-august-8-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/lepodisiran-lilly-acclaim-lp-a-long-duration-sirna-lipoprotein-a-apolipoprotein-a-galnac-annual-dosing-primary-prevention-cardiovascular-outcomes-august-7-2026)

Research & Compounds [

### Lepodisiran: The Once-a-Year Shot Aimed at Lp(a) — Inside Lilly's ACCLAIM-Lp(a) Trial (August 7, 2026)

](/blog/lepodisiran-lilly-acclaim-lp-a-long-duration-sirna-lipoprotein-a-apolipoprotein-a-galnac-annual-dosing-primary-prevention-cardiovascular-outcomes-august-7-2026)

About one in five people inherit high lipoprotein(a) — a genetic driver of heart attacks and strokes that diet, statins, and PCSK9 inhibitors can't touch. Lepodisiran, a long-duration siRNA from Eli Lilly, silences the gene behind it and cut Lp(a) by nearly 94% in Phase 2 — with a single shot lasting a year or more. Its Phase 3 ACCLAIM-Lp(a) trial (~12,500 patients) is the first Lp(a) outcomes study to include people who haven't yet had a cardiovascular event.

PepTracker Pro Team 

August 7, 2026  7 min read 

lepodisiranLY3819469lipoprotein(a)

[Read](/blog/lepodisiran-lilly-acclaim-lp-a-long-duration-sirna-lipoprotein-a-apolipoprotein-a-galnac-annual-dosing-primary-prevention-cardiovascular-outcomes-august-7-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/olpasiran-amgen-oceana-outcomes-sirna-lp-a-lipoprotein-a-apolipoprotein-a-galnac-mrna-silencing-cardiovascular-outcomes-august-6-2026)

Research & Compounds [

### Olpasiran: The Quarterly Injection That Silences Lp(a) at the Gene — Inside Amgen's OCEAN(a)-Outcomes Readout (August 6, 2026)

](/blog/olpasiran-amgen-oceana-outcomes-sirna-lp-a-lipoprotein-a-apolipoprotein-a-galnac-mrna-silencing-cardiovascular-outcomes-august-6-2026)

About one in five people inherit high lipoprotein(a) — a genetic driver of heart attacks and strokes that diet, statins, and PCSK9 inhibitors can't touch. Olpasiran, an siRNA from Amgen, silences the gene behind it and cuts Lp(a) by up to ~97% with a shot every 12 weeks. Its Phase 3 OCEAN(a)-Outcomes trial (~7,000 patients) is one of the pivotal 2026 readouts testing whether lowering Lp(a) actually prevents cardiovascular events.

PepTracker Pro Team 

August 6, 2026  7 min read 

olpasiranAMG 890lipoprotein(a)

[Read](/blog/olpasiran-amgen-oceana-outcomes-sirna-lp-a-lipoprotein-a-apolipoprotein-a-galnac-mrna-silencing-cardiovascular-outcomes-august-6-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/pelacarsen-ionis-novartis-lp-a-antisense-oligonucleotide-apolipoprotein-a-lpa-horizon-cardiovascular-outcomes-tqj230-august-5-2026)

Research & Compounds [

### Pelacarsen: The First Drug That Could Prove Lowering Lp(a) Saves Lives — Inside the Landmark Lp(a)HORIZON Readout (August 5, 2026)

](/blog/pelacarsen-ionis-novartis-lp-a-antisense-oligonucleotide-apolipoprotein-a-lpa-horizon-cardiovascular-outcomes-tqj230-august-5-2026)

About one in five people inherit high lipoprotein(a) — a hidden, genetic driver of heart attacks and strokes that no diet, statin, or PCSK9 inhibitor can touch. Pelacarsen, an antisense oligonucleotide from Ionis and Novartis, cuts it by roughly 80% at the source. Its Lp(a)HORIZON trial (8,323 patients) is the first outcomes study ever to test whether lowering Lp(a) prevents cardiovascular events — and the readout is landing in 2026.

PepTracker Pro Team 

August 5, 2026  7 min read 

pelacarsenTQJ230lipoprotein(a)

[Read](/blog/pelacarsen-ionis-novartis-lp-a-antisense-oligonucleotide-apolipoprotein-a-lpa-horizon-cardiovascular-outcomes-tqj230-august-5-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/avexitide-amylyx-glp1-receptor-antagonist-exendin-9-39-post-bariatric-hypoglycemia-congenital-hyperinsulinism-lucidity-phase3-august-4-2026)

Research & Compounds [

### Avexitide: The GLP-1 Blocker Racing to a Phase 3 Readout — Turning the Obesity Drug Class Upside Down (August 4, 2026)

](/blog/avexitide-amylyx-glp1-receptor-antagonist-exendin-9-39-post-bariatric-hypoglycemia-congenital-hyperinsulinism-lucidity-phase3-august-4-2026)

Every headline GLP-1 drug — semaglutide, tirzepatide, orforglipron — turns the GLP-1 receptor ON. Avexitide turns it OFF. Amylyx's first-in-class GLP-1 receptor antagonist (exendin 9-39) just finished enrolling its pivotal Phase 3 LUCIDITY trial in post-bariatric hypoglycemia, with topline data expected in Q3 2026. Here's why blocking GLP-1 is the whole point.

PepTracker Pro Team 

August 4, 2026  7 min read 

avexitideexendin 9-39GLP-1 receptor antagonist

[Read](/blog/avexitide-amylyx-glp1-receptor-antagonist-exendin-9-39-post-bariatric-hypoglycemia-congenital-hyperinsulinism-lucidity-phase3-august-4-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/kai-7535-hrs-7535-hengrui-kailera-oral-small-molecule-glp1-harbor-1-outstand-2-phase3-liver-safety-obesity-august-2-2026)

Research & Compounds [

### KAI-7535: Another Oral GLP-1 Pill Clears Phase 3 — With a Clean Liver-Safety Readout (August 2, 2026)

](/blog/kai-7535-hrs-7535-hengrui-kailera-oral-small-molecule-glp1-harbor-1-outstand-2-phase3-liver-safety-obesity-august-2-2026)

The oral GLP-1 pill race just added another late-stage entrant. Hengrui's HRS-7535 — developed outside China by Kailera as KAI-7535 — posted up to 10.9% weight loss at Week 44 in a Chinese Phase 3 obesity trial and beat dapagliflozin on blood sugar in a diabetes trial, with no liver-safety signal. Here is what the data show and where it sits versus orforglipron and aleniglipron.

PepTracker Pro Team 

August 2, 2026  7 min read 

KAI-7535HRS-7535Kailera

[Read](/blog/kai-7535-hrs-7535-hengrui-kailera-oral-small-molecule-glp1-harbor-1-outstand-2-phase3-liver-safety-obesity-august-2-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/met-233i-metsera-pfizer-once-monthly-amylin-analog-19-day-half-life-met-097i-combination-obesity-july-31-2026)

Research & Compounds [

### MET-233i: The Once-Monthly Amylin Injection Built to Pair With a Monthly GLP-1 (July 31, 2026)

](/blog/met-233i-metsera-pfizer-once-monthly-amylin-analog-19-day-half-life-met-097i-combination-obesity-july-31-2026)

Most amylin obesity drugs are weekly shots. MET-233i, from Metsera and now Pfizer, is an amylin analog with a ~19-day half-life - the longest reported for the class - that produced up to 8.4% weight loss in Phase 1 and is engineered to be combined with a monthly GLP-1 agonist into one once-monthly injection. Here is what is known, and what is not.

PepTracker Pro Team 

July 31, 2026  7 min read 

MET-233iMetseraPfizer

[Read](/blog/met-233i-metsera-pfizer-once-monthly-amylin-analog-19-day-half-life-met-097i-combination-obesity-july-31-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/asc39-ascletis-oral-small-molecule-amylin-selective-receptor-agonist-eloralintide-like-asc30-fdc-obesity-ind-july-30-2026)

Research & Compounds [

### ASC39: An Oral Amylin Pill Aiming to Match Injectable Amylin Drugs (July 30, 2026)

](/blog/asc39-ascletis-oral-small-molecule-amylin-selective-receptor-agonist-eloralintide-like-asc30-fdc-obesity-ind-july-30-2026)

The best amylin obesity drugs are injections. ASC39, from Ascletis, is a once-daily pill that matched Eli Lilly's injectable eloralintide on amylin potency, selectivity and weight loss in preclinical tests - and it is being paired with an oral GLP-1 agonist into a single tablet. Here is what is known, and what is not.

PepTracker Pro Team 

July 30, 2026  7 min read 

ASC39Ascletisamylin

[Read](/blog/asc39-ascletis-oral-small-molecule-amylin-selective-receptor-agonist-eloralintide-like-asc30-fdc-obesity-ind-july-30-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/wve-007-wave-life-sciences-inhbe-activin-e-galnac-sirna-muscle-sparing-fat-loss-inlight-phase1-alk7-july-29-2026)

Research & Compounds [

### WVE-007: Silencing a Fat-Storage Gene to Lose Fat Without Losing Muscle (July 29, 2026)

](/blog/wve-007-wave-life-sciences-inhbe-activin-e-galnac-sirna-muscle-sparing-fat-loss-inlight-phase1-alk7-july-29-2026)

Most obesity drugs work on appetite. WVE-007 goes after the fat cell itself - it's a single-shot siRNA that silences INHBE, the liver gene behind the hepatokine Activin E, to release the brake on fat burning. In Wave's Phase 1 INLIGHT trial one dose cut visceral fat while lean mass held or rose, hinting at muscle-sparing weight loss and once- or twice-yearly dosing.

PepTracker Pro Team 

July 29, 2026  7 min read 

WVE-007Wave Life SciencesINHBE

[Read](/blog/wve-007-wave-life-sciences-inhbe-activin-e-galnac-sirna-muscle-sparing-fat-loss-inlight-phase1-alk7-july-29-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/alv-200-alveus-amyr3-selective-amylin-agonist-lean-mass-nausea-ctr-selectivity-obesity-july-28-2026)

Research & Compounds [

### ALV-200: The AMYR3-Selective Amylin Agonist Betting That You Can Split Amylin's Benefits From Its Nausea (July 28, 2026)

](/blog/alv-200-alveus-amyr3-selective-amylin-agonist-lean-mass-nausea-ctr-selectivity-obesity-july-28-2026)

Every amylin drug in the clinic today hits the calcitonin receptor along with the amylin receptors - and that CTR activation is a big part of why they make people nauseous. ALV-200, from newly launched Alveus Therapeutics, is built on a sharper bet: that amylin's benefits (weight loss, lean-mass preservation) come mostly from receptor AMYR3, while the nausea comes mostly from CTR. Selectively hit AMYR3, spare CTR, and you might keep the efficacy without the aversion.

PepTracker Pro Team 

July 28, 2026  7 min read 

ALV-200Alveus Therapeuticsamylin

[Read](/blog/alv-200-alveus-amyr3-selective-amylin-agonist-lean-mass-nausea-ctr-selectivity-obesity-july-28-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/imvt-1402-imeroprubart-hl161ans-albumin-sparing-fcrn-blocker-batoclimab-successor-myasthenia-graves-rheumatoid-arthritis-july-27-2026)

Research & Compounds [

### IMVT-1402 (Imeroprubart): The Albumin-Sparing FcRn Blocker Built to Replace Batoclimab (July 27, 2026)

](/blog/imvt-1402-imeroprubart-hl161ans-albumin-sparing-fcrn-blocker-batoclimab-successor-myasthenia-graves-rheumatoid-arthritis-july-27-2026)

Yesterday we told the story of batoclimab - the FcRn blocker that worked in Phase 3 and was deliberately shelved. Today, meet its replacement. IMVT-1402 (imeroprubart) was engineered to lower IgG just as deeply as batoclimab while sparing the serum albumin and LDL cholesterol that sank its predecessor. It is now Immunovant's lead asset, with registrational Graves' and myasthenia readouts due in 2027.

PepTracker Pro Team 

July 27, 2026  8 min read 

IMVT-1402imeroprubartHL161ANS

[Read](/blog/imvt-1402-imeroprubart-hl161ans-albumin-sparing-fcrn-blocker-batoclimab-successor-myasthenia-graves-rheumatoid-arthritis-july-27-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/batoclimab-imvt-1401-rvt-1401-hbm9161-fcrn-blocker-self-injected-myasthenia-cidp-graves-imvt-1402-july-26-2026)

Research & Compounds [

### Batoclimab (IMVT-1401): The FcRn Blocker That Worked in Phase 3 - and Was Deliberately Not Filed (July 26, 2026)

](/blog/batoclimab-imvt-1401-rvt-1401-hbm9161-fcrn-blocker-self-injected-myasthenia-cidp-graves-imvt-1402-july-26-2026)

Three days into the FcRn series we've met three approved blockers. Batoclimab is the fourth - and the odd one out: it hit its Phase 3 myasthenia endpoint, posted best-in-class Graves' remission data, and was then deliberately shelved in favor of a re-engineered successor. Here's why the drug that worked never got filed.

PepTracker Pro Team 

July 26, 2026  8 min read 

batoclimabIMVT-1401RVT-1401

[Read](/blog/batoclimab-imvt-1401-rvt-1401-hbm9161-fcrn-blocker-self-injected-myasthenia-cidp-graves-imvt-1402-july-26-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/rozanolixizumab-rystiggo-ucb7665-fcrn-blocker-subcutaneous-igg4-myasthenia-gravis-musk-cidp-mycaring-july-25-2026)

Research & Compounds [

### Rozanolixizumab (Rystiggo): The Subcutaneous FcRn Blocker That Reached Both Myasthenia Serotypes First (July 25, 2026)

](/blog/rozanolixizumab-rystiggo-ucb7665-fcrn-blocker-subcutaneous-igg4-myasthenia-gravis-musk-cidp-mycaring-july-25-2026)

Two days after efgartigimod and one after nipocalimab, meet the third FcRn blocker. Rozanolixizumab uses the same trick - stop the receptor that recycles your antibodies - but delivered under the skin, in cycles, and it was the first drug approved to cover both the AChR- and MuSK-antibody myasthenia serotypes. It's also an honest lesson in the mechanism's limits: it failed in CIDP.

PepTracker Pro Team 

July 25, 2026  8 min read 

rozanolixizumabrozanolixizumab-noliUCB7665

[Read](/blog/rozanolixizumab-rystiggo-ucb7665-fcrn-blocker-subcutaneous-igg4-myasthenia-gravis-musk-cidp-mycaring-july-25-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/nipocalimab-imaavy-m281-fcrn-blocker-aglycosylated-antibody-myasthenia-gravis-sjogrens-hdfn-waiha-vivacity-dahlias-unity-july-24-2026)

Research & Compounds [

### Nipocalimab (Imaavy): The FcRn Blocker That Went Everywhere - From Myasthenia Gravis to the Womb (July 24, 2026)

](/blog/nipocalimab-imaavy-m281-fcrn-blocker-aglycosylated-antibody-myasthenia-gravis-sjogrens-hdfn-waiha-vivacity-dahlias-unity-july-24-2026)

A day after efgartigimod, meet the other FcRn blocker. Nipocalimab uses the same trick - stop the receptor that recycles your antibodies - but as a full antibody, dosed continuously, and pushed into places no rival has gone: rheumatology, hematology, and even pregnancy.

PepTracker Pro Team 

July 24, 2026  8 min read 

nipocalimabnipocalimab-aahuM281

[Read](/blog/nipocalimab-imaavy-m281-fcrn-blocker-aglycosylated-antibody-myasthenia-gravis-sjogrens-hdfn-waiha-vivacity-dahlias-unity-july-24-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/efgartigimod-vyvgart-argx-113-fcrn-antagonist-igg-recycling-myasthenia-gravis-cidp-seronegative-adapt-seron-july-23-2026)

Research & Compounds [

### Efgartigimod (Vyvgart): The Antibody Fragment That Treats Autoimmune Disease by Deleting Your Own Antibodies (July 23, 2026)

](/blog/efgartigimod-vyvgart-argx-113-fcrn-antagonist-igg-recycling-myasthenia-gravis-cidp-seronegative-adapt-seron-july-23-2026)

Most autoimmune drugs suppress the whole immune system. Efgartigimod does something narrower and stranger: it blocks the receptor that recycles your antibodies, so your own pathogenic IgG gets thrown out with the trash. In May 2026 the FDA made it the first and only myasthenia gravis drug approved for every antibody serotype.

PepTracker Pro Team 

July 23, 2026  8 min read 

efgartigimodefgartigimod alfaARGX-113

[Read](/blog/efgartigimod-vyvgart-argx-113-fcrn-antagonist-igg-recycling-myasthenia-gravis-cidp-seronegative-adapt-seron-july-23-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/efinopegdutide-mk-6024-hanmi-merck-glp1-glucagon-dual-agonist-mash-liver-fat-semaglutide-head-to-head-july-22-2026)

Research & Compounds [

### Efinopegdutide (MK-6024): The GLP-1/Glucagon Dual That Beat Semaglutide on Liver Fat (July 22, 2026)

](/blog/efinopegdutide-mk-6024-hanmi-merck-glp1-glucagon-dual-agonist-mash-liver-fat-semaglutide-head-to-head-july-22-2026)

GLP-1 drugs like semaglutide shrink liver fat mostly by making you lose weight. Efinopegdutide adds a glucagon arm that burns fat inside the liver directly - and in a head-to-head Phase 2a trial it cut liver fat by 72.7% versus semaglutide's 42.3% at matched weight loss. Here is how the oxyntomodulin-based dual agonist works, why Merck redirected a twice-shelved Hanmi molecule at MASH, and what still has to be proven on biopsy.

PepTracker Pro Team 

July 22, 2026  8 min read 

efinopegdutideMK-6024HM12525A

[Read](/blog/efinopegdutide-mk-6024-hanmi-merck-glp1-glucagon-dual-agonist-mash-liver-fat-semaglutide-head-to-head-july-22-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/difelikefalin-korsuva-kapruvia-peripheral-kappa-opioid-agonist-ckd-pruritus-kalm-notalgia-paresthetica-july-21-2026)

Research & Compounds [

### Difelikefalin (Korsuva): The Opioid Engineered So It Cannot Reach Your Brain (July 21, 2026)

](/blog/difelikefalin-korsuva-kapruvia-peripheral-kappa-opioid-agonist-ckd-pruritus-kalm-notalgia-paresthetica-july-21-2026)

Kappa opioid agonists have suppressed itch since the 1980s. None of them made it, because central kappa activation causes dysphoria and hallucinations. Difelikefalin is four D-amino acids assembled specifically so the molecule cannot get into the brain - keeping the receptor and discarding the compartment. Here is what KALM-1 and KALM-2 actually showed in dialysis itch, why antihistamines never worked, and what the failed atopic dermatitis trial tells you about the mechanism.

PepTracker Pro Team 

July 21, 2026  9 min read 

difelikefalinKorsuvaKapruvia

[Read](/blog/difelikefalin-korsuva-kapruvia-peripheral-kappa-opioid-agonist-ckd-pruritus-kalm-notalgia-paresthetica-july-21-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/abaloparatide-tymlos-pthrp-analog-osteoanabolic-active-activextend-wearable-rg-conformation-july-20-2026)

Research & Compounds [

### Abaloparatide (Tymlos): The PTHrP Analog That Builds Bone by Letting Go of the Receptor Faster (July 20, 2026)

](/blog/abaloparatide-tymlos-pthrp-analog-osteoanabolic-active-activextend-wearable-rg-conformation-july-20-2026)

Abaloparatide and teriparatide bind the same receptor. Abaloparatide prefers its transient RG conformation, so each injection signals for a shorter time - and a shorter signal is what widens the anabolic window. In Phase 3 ACTIVE that translated into an 86% reduction in new vertebral fractures. Here is what ACTIVE and ACTIVExtend actually established, why the osteosarcoma boxed warning came off in 2021, and why the transdermal patch built real bone and still failed.

PepTracker Pro Team 

July 20, 2026  9 min read 

abaloparatideTymlosPTHrP

[Read](/blog/abaloparatide-tymlos-pthrp-analog-osteoanabolic-active-activextend-wearable-rg-conformation-july-20-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/palopegteriparatide-yorvipath-transcon-pth-prodrug-chronic-hypoparathyroidism-pathway-path-forward-july-19-2026)

Research & Compounds [

### Palopegteriparatide (Yorvipath): Why the Same PTH Peptide Becomes a Different Drug When You Change the Release Curve (July 19, 2026)

](/blog/palopegteriparatide-yorvipath-transcon-pth-prodrug-chronic-hypoparathyroidism-pathway-path-forward-july-19-2026)

Teriparatide and palopegteriparatide deliver the same 34-amino-acid PTH fragment. One is an osteoporosis drug; the other is the first real hormone replacement for chronic hypoparathyroidism. The difference is an auto-cleaving PEG carrier that turns a daily spike into 24 hours of flat physiologic exposure - and in Phase 3 PaTHway it let 78.7% of patients reach normal serum calcium while coming off calcium and calcitriol entirely, versus 4.8% on placebo.

PepTracker Pro Team 

July 19, 2026  9 min read 

palopegteriparatideYorvipathTransCon PTH

[Read](/blog/palopegteriparatide-yorvipath-transcon-pth-prodrug-chronic-hypoparathyroidism-pathway-path-forward-july-19-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/sotatercept-winrevair-actriia-fc-activin-signaling-inhibitor-pah-stellar-zenith-hyperion-july-18-2026)

Research & Compounds [

### Sotatercept (Winrevair): The Activin Trap That Made Pulmonary Arterial Hypertension a Treatable Disease, Not Just a Managed One (July 18, 2026)

](/blog/sotatercept-winrevair-actriia-fc-activin-signaling-inhibitor-pah-stellar-zenith-hyperion-july-18-2026)

Merck's sotatercept (Winrevair) is a fusion protein that traps activin A, activin B, myostatin and GDF-11 - and it changed what pulmonary arterial hypertension therapy can aim for. STELLAR delivered a 40.8-meter gain in 6-minute walk distance; ZENITH cut death, transplant and hospitalization by 76% in the sickest patients and led to an expanded FDA label on October 27, 2025. Here is how the broadest activin-axis drug compares with the selective antibodies chasing the same biology.

PepTracker Pro Team 

July 18, 2026  9 min read 

sotaterceptWinrevairMerck

[Read](/blog/sotatercept-winrevair-actriia-fc-activin-signaling-inhibitor-pah-stellar-zenith-hyperion-july-18-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/garetosmab-regn2477-regeneron-activin-a-antibody-optima-fop-courage-muscle-preservation-july-17-2026)

Research & Compounds [

### Garetosmab: Regeneron's Activin A Antibody Nearly Shuts Off Bone Growth in FOP - and Helps Save Muscle in Obesity (July 17, 2026)

](/blog/garetosmab-regn2477-regeneron-activin-a-antibody-optima-fop-courage-muscle-preservation-july-17-2026)

Regeneron's anti-activin A antibody garetosmab (REGN2477) cut new bone lesions by ~90-94% and their volume by more than 99% in the Phase 3 OPTIMA trial for the ultra-rare disease FOP - and its BLA is now under FDA Priority Review with an August 2026 decision date. The same activin A blockade also makes it the muscle-sparing partner to trevogrumab in the COURAGE obesity program.

PepTracker Pro Team 

July 17, 2026  8 min read 

garetosmabREGN2477Regeneron

[Read](/blog/garetosmab-regn2477-regeneron-activin-a-antibody-optima-fop-courage-muscle-preservation-july-17-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/trevogrumab-regn1033-regeneron-myostatin-antibody-courage-semaglutide-muscle-preservation-lean-mass-july-16-2026)

Research & Compounds [

### Trevogrumab: Regeneron's Myostatin Antibody Aims to Keep the Muscle On During GLP-1 Weight Loss (July 16, 2026)

](/blog/trevogrumab-regn1033-regeneron-myostatin-antibody-courage-semaglutide-muscle-preservation-lean-mass-july-16-2026)

GLP-1 drugs melt away fat - but about a third of the weight lost is muscle. Regeneron's anti-myostatin antibody trevogrumab (REGN1033) is designed to fix that. In the Phase 2 COURAGE trial, adding it to semaglutide halved lean-mass loss, and a triplet with garetosmab preserved over 80% of muscle while deepening fat loss. Here's where it fits in the muscle-preservation race.

PepTracker Pro Team 

July 16, 2026  8 min read 

trevogrumabREGN1033Regeneron

[Read](/blog/trevogrumab-regn1033-regeneron-myostatin-antibody-courage-semaglutide-muscle-preservation-lean-mass-july-16-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/cx11-corxel-vincentage-oral-small-molecule-glp1-phase2-obesity-11-percent-weight-loss-july-15-2026)

Research & Compounds [

### CX11: Corxel's Oral Small-Molecule GLP-1 Posts 11.5% Weight Loss - and a Surprisingly Low Vomiting Rate (July 15, 2026)

](/blog/cx11-corxel-vincentage-oral-small-molecule-glp1-phase2-obesity-11-percent-weight-loss-july-15-2026)

Corxel's once-daily oral GLP-1 pill CX11 hit its Phase 2 endpoints with up to 11.5% weight loss at 36 weeks - and stood out most for what it didn't do: a vomiting rate of just 12-16% and no hepatic safety signal across 1,500+ participants. Here is where it fits in the crowded oral GLP-1 race.

PepTracker Pro Team 

July 15, 2026  8 min read 

CX11oral GLP-1small-molecule GLP-1

[Read](/blog/cx11-corxel-vincentage-oral-small-molecule-glp1-phase2-obesity-11-percent-weight-loss-july-15-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/apitegromab-srk-015-scholar-rock-myostatin-inhibitor-sma-sapphire-embraze-muscle-preservation-july-14-2026)

Research & Compounds [

### Apitegromab (SRK-015): The First Muscle-Targeted Myostatin Antibody to Win a Phase 3 - in SMA, and Now Obesity (July 14, 2026)

](/blog/apitegromab-srk-015-scholar-rock-myostatin-inhibitor-sma-sapphire-embraze-muscle-preservation-july-14-2026)

For two decades, drugging myostatin - the body's brake on muscle growth - was a graveyard of failed trials. Apitegromab changed that. Scholar Rock's antibody binds only the inactive precursor forms of myostatin, and in the Phase 3 SAPPHIRE trial it became the first muscle-targeted therapy to improve motor function in spinal muscular atrophy on top of SMN drugs. Now the same mechanism is showing up in obesity: in Phase 2 EMBRAZE, apitegromab preserved ~55% more lean mass during tirzepatide weight loss. Here is how it works, what the data show, and where its September 30, 2026 FDA decision stands.

PepTracker Pro Team 

July 14, 2026  9 min read 

apitegromabSRK-015Scholar Rock

[Read](/blog/apitegromab-srk-015-scholar-rock-myostatin-inhibitor-sma-sapphire-embraze-muscle-preservation-july-14-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/efimosfermin-alfa-bos-580-gsk-long-acting-fgf21-analog-mash-once-monthly-zenith-july-13-2026)

Research & Compounds [

### Efimosfermin Alfa (BOS-580): GSK's Once-Monthly FGF21 Analog Enters the MASH Race (July 13, 2026)

](/blog/efimosfermin-alfa-bos-580-gsk-long-acting-fgf21-analog-mash-once-monthly-zenith-july-13-2026)

The FGF21 race for the liver now has three front-runners - and efimosfermin alfa is the one you inject just once a month. Acquired by GSK from Boston Pharmaceuticals in a deal worth up to $2 billion, this long-acting FGF21 analog improved fibrosis in roughly 45% of F2-F3 MASH patients and resolved MASH in about 68% in a 24-week Phase 2 trial. Here is how efimosfermin is built, what the data show, and how monthly dosing stacks up against weekly efruxifermin and pegozafermin as the Phase 3 ZENITH program runs.

PepTracker Pro Team 

July 13, 2026  8 min read 

efimosfermin alfaefimosferminBOS-580

[Read](/blog/efimosfermin-alfa-bos-580-gsk-long-acting-fgf21-analog-mash-once-monthly-zenith-july-13-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/efruxifermin-efx-akr-001-akero-fc-fgf21-fusion-mash-cirrhosis-reversal-synchrony-july-12-2026)

Research & Compounds [

### Efruxifermin (EFX): The Fc-FGF21 Fusion Betting It Can Reverse MASH Cirrhosis (July 12, 2026)

](/blog/efruxifermin-efx-akr-001-akero-fc-fgf21-fusion-mash-cirrhosis-reversal-synchrony-july-12-2026)

The incretins own the obesity headlines, but the liver has its own race - and it is between two FGF21 analogs. Efruxifermin (EFX) is Akero's bivalent Fc-FGF21 fusion protein, dosed once weekly, and its ambition is bigger than cutting liver fat: in Phase 2b it improved fibrosis in three-quarters of pre-cirrhotic MASH patients and reversed compensated cirrhosis in roughly two of five. Here is how the drug is built, what the HARMONY and SYMMETRY data show, and how it stacks up against pegozafermin as the Phase 3 SYNCHRONY program reads out.

PepTracker Pro Team 

July 12, 2026  8 min read 

efruxiferminEFXAKR-001

[Read](/blog/efruxifermin-efx-akr-001-akero-fc-fgf21-fusion-mash-cirrhosis-reversal-synchrony-july-12-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/pegozafermin-bio89-100-glycopegylated-fgf21-analog-mash-fibrosis-roche-89bio-july-10-2026)

Research & Compounds [

### Pegozafermin (BIO89-100): The glycoPEGylated FGF21 Analog Betting on Fibrosis Reversal in MASH (July 10, 2026)

](/blog/pegozafermin-bio89-100-glycopegylated-fgf21-analog-mash-fibrosis-roche-89bio-july-10-2026)

Most of the obesity headlines belong to the incretins. Pegozafermin (BIO89-100) takes a different route to the liver: a glycoPEGylated FGF21 analog engineered for a ~55-100 hour half-life and weekly-to-biweekly dosing. In Phase 2b ENLIVEN it improved fibrosis and resolved MASH at rates far above placebo - and its 2025 acquisition by Roche put a major spotlight on the FGF21 mechanism. Here's how the drug works, what the data show, and how it fits alongside efruxifermin and the incretin-based MASH contenders.

PepTracker Pro Team 

July 10, 2026  8 min read 

pegozaferminBIO89-100FGF21

[Read](/blog/pegozafermin-bio89-100-glycopegylated-fgf21-analog-mash-fibrosis-roche-89bio-july-10-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/efocipegtrutide-hm15211-hanmi-glp1-gip-glucagon-triple-agonist-mash-liver-fibrosis-july-09-2026)

Research & Compounds [

### Efocipegtrutide (HM15211): Hanmi's GLP-1/GIP/Glucagon Triple Agonist Aims at Liver Disease, Not Just Weight (July 9, 2026)

](/blog/efocipegtrutide-hm15211-hanmi-glp1-gip-glucagon-triple-agonist-mash-liver-fibrosis-july-09-2026)

Most triple agonists chase weight loss. Hanmi's efocipegtrutide (HM15211) is built for the liver: a once-weekly GLP-1/GIP/glucagon agonist whose glucagon arm drives energy expenditure and direct anti-fibrotic effects in MASH. Here's how the LAPSCovery Fc-fusion design works, what the liver-fat data show, and why its MASH-first, orphan-designated positioning sets it apart from retatrutide.

PepTracker Pro Team 

July 9, 2026  8 min read 

efocipegtrutideHM15211Hanmi Pharmaceutical

[Read](/blog/efocipegtrutide-hm15211-hanmi-glp1-gip-glucagon-triple-agonist-mash-liver-fibrosis-july-09-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/ct-388-ro7795068-roche-carmot-dual-glp1-gip-signal-biased-agonist-obesity-phase-3-july-08-2026)

Research & Compounds [

### CT-388: Roche's Signal-Biased Dual GLP-1/GIP Agonist Heads Into Phase 3 for Obesity (July 8, 2026)

](/blog/ct-388-ro7795068-roche-carmot-dual-glp1-gip-signal-biased-agonist-obesity-phase-3-july-08-2026)

Roche entered the obesity race late, but its Carmot-acquired dual GLP-1/GIP agonist CT-388 posted a placebo-adjusted 22.5% weight loss in Phase 2 and moved into Phase 3 in 2026. Here's what makes CT-388's 'signal-biased' mechanism distinct, what the QWINT-class data actually show, and how it stacks up against tirzepatide.

PepTracker Pro Team 

July 8, 2026  8 min read 

CT-388CT388RO7795068

[Read](/blog/ct-388-ro7795068-roche-carmot-dual-glp1-gip-signal-biased-agonist-obesity-phase-3-july-08-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/insulin-efsitora-alfa-ly3209590-once-weekly-basal-insulin-fc-fusion-qwint-type-2-diabetes-july-07-2026)

Research & Compounds [

### Insulin Efsitora Alfa: The Once-Weekly Basal Insulin Fc-Fusion Heading for an FDA Decision (July 7, 2026)

](/blog/insulin-efsitora-alfa-ly3209590-once-weekly-basal-insulin-fc-fusion-qwint-type-2-diabetes-july-07-2026)

Basal insulin has been a daily shot for a century. Insulin efsitora alfa fuses a single-chain insulin to an antibody Fc fragment so one injection lasts a week - a ~17-day half-life and a flat, stable profile. Here's how the Fc-fusion design works, what the Phase 3 QWINT trials showed in type 2 and type 1 diabetes (including a real hypoglycemia caveat), and why its FDA decision this quarter matters.

PepTracker Pro Team 

July 7, 2026  8 min read 

insulin efsitora alfaefsitoraLY3209590

[Read](/blog/insulin-efsitora-alfa-ly3209590-once-weekly-basal-insulin-fc-fusion-qwint-type-2-diabetes-july-07-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/trofinetide-daybue-igf1-gpe-analog-peptide-rett-syndrome-mecp2-lavender-lotus-july-06-2026)

Research & Compounds [

### Trofinetide: The IGF-1 Tripeptide Analog That Became the First Approved Medicine for Rett Syndrome (July 6, 2026)

](/blog/trofinetide-daybue-igf1-gpe-analog-peptide-rett-syndrome-mecp2-lavender-lotus-july-06-2026)

Rett syndrome comes from loss of MECP2, a master gene-regulator - too broad a problem to fix with a single switch. Trofinetide doesn't correct the mutation; it mimics a tiny fragment of IGF-1 (the tripeptide GPE) to restore neurotrophic and anti-inflammatory tone across many pathways at once. Here's how the first approved peptide for Rett syndrome works, what the LAVENDER and LOTUS data show, and what changed in 2026.

PepTracker Pro Team 

July 6, 2026  8 min read 

trofinetideDaybueNNZ-2566

[Read](/blog/trofinetide-daybue-igf1-gpe-analog-peptide-rett-syndrome-mecp2-lavender-lotus-july-06-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/vosoritide-voxzogo-cnp-analog-peptide-achondroplasia-fgfr3-npr-b-bmn-333-july-05-2026)

Research & Compounds [

### Vosoritide: The CNP-Analog Peptide That Rebalances the Growth Plate in Achondroplasia (July 5, 2026)

](/blog/vosoritide-voxzogo-cnp-analog-peptide-achondroplasia-fgfr3-npr-b-bmn-333-july-05-2026)

Achondroplasia comes from an FGFR3 receptor stuck in the 'on' position, pressing the brake on the growth plate. Vosoritide doesn't block that faulty receptor - it supplies extra of the body's natural counter-signal, C-type natriuretic peptide, to lift the brake. Here's how the first approved peptide for achondroplasia works, what the data show, and where the field is heading.

PepTracker Pro Team 

July 5, 2026  8 min read 

vosoritideVoxzogoBMN 111

[Read](/blog/vosoritide-voxzogo-cnp-analog-peptide-achondroplasia-fgfr3-npr-b-bmn-333-july-05-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/rusfertide-ptg-300-hepcidin-mimetic-peptide-polycythemia-vera-ferroportin-verify-july-04-2026)

Research & Compounds [

### Rusfertide: The Hepcidin-Mimetic Peptide That Could End Routine Blood-Letting for Polycythemia Vera (July 4, 2026)

](/blog/rusfertide-ptg-300-hepcidin-mimetic-peptide-polycythemia-vera-ferroportin-verify-july-04-2026)

Polycythemia vera makes the marrow churn out too many red cells, and the standard fix is old-fashioned blood-letting. Rusfertide takes a different route: it's a synthetic mimic of hepcidin, the hormone that governs iron. By starving the marrow of iron, this weekly peptide injection kept 77% of patients phlebotomy-free in Phase 3 - and it's now under FDA Priority Review with a decision due in late 2026.

PepTracker Pro Team 

July 4, 2026  8 min read 

rusfertidePTG-300hepcidin

[Read](/blog/rusfertide-ptg-300-hepcidin-mimetic-peptide-polycythemia-vera-ferroportin-verify-july-04-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/pegcetacoplan-empaveli-syfovre-complement-c3-cyclic-peptide-c3g-approval-july-03-2026)

Research & Compounds [

### Pegcetacoplan: The Cyclic Peptide That Tamed Complement C3 - and Just Became the First Drug for Two Rare Kidney Diseases (July 3, 2026)

](/blog/pegcetacoplan-empaveli-syfovre-complement-c3-cyclic-peptide-c3g-approval-july-03-2026)

Pegcetacoplan started as compstatin, a lab peptide that grabs complement C3. Engineered into a PEGylated cyclic-peptide dimer, it's now approved for PNH, geographic atrophy, and - since July 2025 - as the first treatment for the rare kidney diseases C3G and IC-MPGN. Here's how a peptide reached the market three times over.

PepTracker Pro Team 

July 3, 2026  8 min read 

pegcetacoplanAPL-2Empaveli

[Read](/blog/pegcetacoplan-empaveli-syfovre-complement-c3-cyclic-peptide-c3g-approval-july-03-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/dapiglutide-zp7570-dual-glp1-glp2-agonist-obesity-gut-barrier-paused-july-02-2026)

Research & Compounds [

### Dapiglutide: The Dual GLP-1/GLP-2 Obesity Peptide That Bet on the Gut — and Got Paused (July 2, 2026)

](/blog/dapiglutide-zp7570-dual-glp1-glp2-agonist-obesity-gut-barrier-paused-july-02-2026)

Dapiglutide (ZP7570) is a once-weekly dual GLP-1/GLP-2 receptor agonist that aimed to combine appetite-driven weight loss with a stronger gut barrier and less inflammation. It reached 11.6% weight loss at 28 weeks — then Zealand Pharma paused it. Here's the honest story and why it still matters.

PepTracker Pro Team 

July 2, 2026  8 min read 

dapiglutideZP7570GLP-1

[Read](/blog/dapiglutide-zp7570-dual-glp1-glp2-agonist-obesity-gut-barrier-paused-july-02-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/efzofitimod-atyr1923-nrp2-immunomodulatory-peptide-pulmonary-sarcoidosis-efzo-fit-july-01-2026)

Research & Compounds [

### Efzofitimod: A First-in-Class Immunomodulatory Peptide Aims to Take Sarcoidosis Patients Off Steroids (July 1, 2026)

](/blog/efzofitimod-atyr1923-nrp2-immunomodulatory-peptide-pulmonary-sarcoidosis-efzo-fit-july-01-2026)

Efzofitimod (ATYR1923) is a first-in-class immunomodulatory peptide that binds neuropilin-2 to calm lung inflammation in pulmonary sarcoidosis. Its Phase 3 EFZO-FIT trial missed its primary steroid-reduction endpoint in 2025 but showed benefit on symptoms and lung function — here is what it is, how it works, and where it stands in 2026.

PepTracker Pro Team 

July 1, 2026  9 min read 

efzofitimodATYR1923iMod.Fc

[Read](/blog/efzofitimod-atyr1923-nrp2-immunomodulatory-peptide-pulmonary-sarcoidosis-efzo-fit-july-01-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/glepaglutide-glp2-analog-short-bowel-syndrome-parenteral-support-zealand-june-30-2026)

Research & Compounds [

### Glepaglutide: The Long-Acting GLP-2 Peptide Trying to Free Short Bowel Patients From IV Nutrition (June 30, 2026)

](/blog/glepaglutide-glp2-analog-short-bowel-syndrome-parenteral-support-zealand-june-30-2026)

Glepaglutide is a long-acting GLP-2 analog dosed once or twice weekly that helps the remaining gut absorb more nutrients in short bowel syndrome — cutting, and sometimes eliminating, the need for IV nutrition. Here is where it stands in 2026 after positive Phase 3 data, an FDA Complete Response Letter, and a European filing.

PepTracker Pro Team 

June 30, 2026  9 min read 

glepaglutideZP1848GLP-2

[Read](/blog/glepaglutide-glp2-analog-short-bowel-syndrome-parenteral-support-zealand-june-30-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/apraglutide-once-weekly-glp2-analog-short-bowel-syndrome-stars-ironwood-june-30-2026)

Research & Compounds [

### Apraglutide: The Once-Weekly GLP-2 Peptide for Short Bowel Syndrome — and Why the FDA Wants One More Trial (June 30, 2026)

](/blog/apraglutide-once-weekly-glp2-analog-short-bowel-syndrome-stars-ironwood-june-30-2026)

Apraglutide is a once-weekly GLP-2 analog that helps the remaining gut absorb more in short bowel syndrome — the least frequent dosing of any drug in its class. Its Phase 3 STARS trial worked, but in 2026 it still needs an FDA-required confirmatory trial. Here is where it stands.

PepTracker Pro Team 

June 30, 2026  8 min read 

apraglutideFE 203799GLP-2

[Read](/blog/apraglutide-once-weekly-glp2-analog-short-bowel-syndrome-stars-ironwood-june-30-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/zosurabalpin-rg6006-macrocyclic-peptide-antibiotic-crab-acinetobacter-lps-transport-june-27-2026)

Research & Compounds [

### Zosurabalpin (RG6006): The First-in-Class Macrocyclic Peptide Antibiotic Taking on a Critical Superbug (June 27, 2026)

](/blog/zosurabalpin-rg6006-macrocyclic-peptide-antibiotic-crab-acinetobacter-lps-transport-june-27-2026)

Zosurabalpin (RG6006) is the first antibiotic of a brand-new structural class in decades — a tethered macrocyclic peptide that kills carbapenem-resistant Acinetobacter baumannii by jamming the bacterium's LPS transporter. Here's how it works and why its move into Phase 3 matters.

PepTracker Pro Team 

June 27, 2026  9 min read 

zosurabalpinRG6006RO7223280

[Read](/blog/zosurabalpin-rg6006-macrocyclic-peptide-antibiotic-crab-acinetobacter-lps-transport-june-27-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/setmelanotide-imcivree-mc4r-agonist-peptide-rare-genetic-hypothalamic-obesity-june-26-2026)

Research & Compounds [

### Setmelanotide (Imcivree): The MC4R Peptide That Treats Obesity the GLP-1 Drugs Can't (June 26, 2026)

](/blog/setmelanotide-imcivree-mc4r-agonist-peptide-rare-genetic-hypothalamic-obesity-june-26-2026)

Setmelanotide (Imcivree) is a cyclic octapeptide that activates the brain's MC4R appetite switch directly — treating rare genetic and post-tumor hypothalamic obesity that GLP-1 drugs were never designed for. In March 2026 the FDA expanded it to acquired hypothalamic obesity, making it the first and only approved therapy for that condition.

PepTracker Pro Team 

June 26, 2026  9 min read 

setmelanotideImcivreeMC4R agonist

[Read](/blog/setmelanotide-imcivree-mc4r-agonist-peptide-rare-genetic-hypothalamic-obesity-june-26-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/zilucoplan-zilbrysq-macrocyclic-peptide-complement-c5-myasthenia-gravis-june-23-2026)

Research & Compounds [

### Zilucoplan (Zilbrysq): The Self-Injectable Peptide That Blocks Complement in Myasthenia Gravis (June 23, 2026)

](/blog/zilucoplan-zilbrysq-macrocyclic-peptide-complement-c5-myasthenia-gravis-june-23-2026)

Zilucoplan is a macrocyclic peptide that switches off the final step of the complement cascade. Unlike the IV antibodies that came before it, patients inject it under the skin once a day. Here is how it works and what the evidence shows.

PepTracker Pro Team 

June 23, 2026  9 min read 

zilucoplanZilbrysqRA101495

[Read](/blog/zilucoplan-zilbrysq-macrocyclic-peptide-complement-c5-myasthenia-gravis-june-23-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/davunetide-nap-microtubule-tau-neuroprotection-adnp-syndrome-june-22-2026)

Research & Compounds [

### Davunetide (NAP): The Tau-Targeting Microtubule Peptide Getting a Second Act in 2026 (June 22, 2026)

](/blog/davunetide-nap-microtubule-tau-neuroprotection-adnp-syndrome-june-22-2026)

Davunetide is an eight-amino-acid peptide that stabilizes microtubules and lowers tau phosphorylation. It failed a major tauopathy trial — and in 2026 it is back, aimed at a rare genetic disease. Here is what the research actually shows.

PepTracker Pro Team 

June 22, 2026  9 min read 

davunetideNAPNAPVSIPQ

[Read](/blog/davunetide-nap-microtubule-tau-neuroprotection-adnp-syndrome-june-22-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/humanin-mitochondrial-derived-peptide-longevity-neuroprotection-june-21-2026)

Research & Compounds [

### Humanin: The Mitochondrial-Derived Peptide Behind the 2026 Longevity-Biomarker Buzz (June 21, 2026)

](/blog/humanin-mitochondrial-derived-peptide-longevity-neuroprotection-june-21-2026)

Humanin is an endogenous peptide encoded by your mitochondria that protects neurons, declines with age, and runs high in centenarians. Here is what the research actually shows in 2026 — and what it does not.

PepTracker Pro Team 

June 21, 2026  9 min read 

humaninHNMT-RNR2

[Read](/blog/humanin-mitochondrial-derived-peptide-longevity-neuroprotection-june-21-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/met-097i-pfizer-metsera-monthly-glp1-vesper-3-june-20-2026)

Research & Compounds [

### MET-097i: Pfizer's Once-Monthly GLP-1 and the Race for Longer Dosing Intervals (June 20, 2026)

](/blog/met-097i-pfizer-metsera-monthly-glp1-vesper-3-june-20-2026)

Pfizer's newly acquired MET-097i is an ultra-long-acting GLP-1 designed for once-monthly maintenance dosing. Here's what the VESPER-3 Phase 2b data show, why the dosing interval matters, and what to watch as ~10 Phase 3 trials begin in 2026.

PepTracker Pro Team 

June 20, 2026  8 min read 

MET-097iPF-'3944Metsera

[Read](/blog/met-097i-pfizer-metsera-monthly-glp1-vesper-3-june-20-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/pluvicto-lutetium-177-psma-radioligand-prostate-cancer-psmaddition-june-19-2026)

Research & Compounds [

### Pluvicto (Lutetium-177 PSMA): The Targeted Radiation Drug Reshaping Prostate Cancer — and Is It Really a Peptide? (June 19, 2026)

](/blog/pluvicto-lutetium-177-psma-radioligand-prostate-cancer-psmaddition-june-19-2026)

Pluvicto (lutetium-177 vipivotide tetraxetan) is one of oncology's most talked-about 'peptide-targeted' drugs — a radioligand that delivers radiation straight to prostate-cancer cells. In 2026 the Phase 3 PSMAddition trial pushed it into earlier disease. Here is how it works, what the new data show, and why calling it a 'peptide' deserves an asterisk.

PepTracker Pro Team 

June 19, 2026  8 min read 

Pluvictolutetium-177177Lu-PSMA-617

[Read](/blog/pluvicto-lutetium-177-psma-radioligand-prostate-cancer-psmaddition-june-19-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/motixafortide-aphexda-cxcr4-peptide-stem-cell-mobilization-pancreatic-cancer-june-17-2026)

Research & Compounds [

### Motixafortide (Aphexda): The FDA-Approved Peptide Working in Cancer Care — and Why Not Every Peptide Is About Weight Loss (June 17, 2026)

](/blog/motixafortide-aphexda-cxcr4-peptide-stem-cell-mobilization-pancreatic-cancer-june-17-2026)

Most peptide headlines are about weight loss. Motixafortide (Aphexda, BL-8040) is a different kind of story: an FDA-approved cyclic peptide used in cancer care to mobilize stem cells for transplant — and now being tested against pancreatic cancer. Here's how it works and why it matters.

PepTracker Pro Team 

June 17, 2026  8 min read 

motixafortideaphexdaBL-8040

[Read](/blog/motixafortide-aphexda-cxcr4-peptide-stem-cell-mobilization-pancreatic-cancer-june-17-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/klotho-longevity-protein-brain-aging-cognition-phase-1-trial-june-16-2026)

Research & Compounds [

### Klotho: The 'Longevity Hormone' Being Tested to Slow Brain Aging — What the Science Actually Shows (June 16, 2026)

](/blog/klotho-longevity-protein-brain-aging-cognition-phase-1-trial-june-16-2026)

Klotho is a longevity hormone your body makes naturally. A single low-dose injection improved memory in aged monkeys, and a Phase 1 trial is now testing it in older adults. Here's what the evidence shows — and why klotho is a large protein, not a peptide you can buy.

PepTracker Pro Team 

June 16, 2026  9 min read 

klothoalpha-klotholongevity hormone

[Read](/blog/klotho-longevity-protein-brain-aging-cognition-phase-1-trial-june-16-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/oral-glp1-pill-race-conveglipron-hdm1002-vs-orforglipron-danuglipron-june-15-2026)

Research & Compounds [

### The Oral GLP-1 Pill Race Widens: Conveglipron (HDM1002) Joins Orforglipron in the Hunt for a Needle-Free Weight-Loss Drug — June 15, 2026

](/blog/oral-glp1-pill-race-conveglipron-hdm1002-vs-orforglipron-danuglipron-june-15-2026)

Conveglipron (HDM1002) is an oral, once-daily small-molecule GLP-1 receptor agonist from Huadong Medicine now in Phase 2 for obesity and Phase 3 for type 2 diabetes. Here's how the GLP-1 'pill' race is shaping up against orforglipron and danuglipron — and why an oral small molecule is not the same thing as a peptide.

PepTracker Pro Team 

June 15, 2026  9 min read 

conveglipronHDM1002oral GLP-1

[Read](/blog/oral-glp1-pill-race-conveglipron-hdm1002-vs-orforglipron-danuglipron-june-15-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/oral-amylin-race-accg-2671-vs-amycretin-eloralintide-pill-vs-injection-june-14-2026)

Research & Compounds [

### The Race to Put Amylin in a Pill: ACCG-2671 Enters the Clinic, and How Oral Amylin Stacks Up Against Injectable Amylin and GLP-1 — June 14, 2026

](/blog/oral-amylin-race-accg-2671-vs-amycretin-eloralintide-pill-vs-injection-june-14-2026)

Amylin has become the obesity field's favorite non-GLP-1 mechanism — but almost every amylin drug is an injection. Structure Therapeutics just started first-in-human testing of ACCG-2671, an oral, once-daily small-molecule amylin agonist. Here's what amylin does, why an oral version matters, how ACCG-2671 compares to amycretin, eloralintide, cagrilintide, and petrelintide, and why 'in a Phase 1 trial' is very different from 'available to buy.'

PepTracker Pro Team 

June 14, 2026  9 min read 

ACCG-2671oral amylinamylin receptor agonist

[Read](/blog/oral-amylin-race-accg-2671-vs-amycretin-eloralintide-pill-vs-injection-june-14-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/pep19-endocannabinoid-peptide-visceral-fat-sleep-vs-glp1-june-13-2026)

Research & Compounds [

### A Peptide That Targeted Visceral Fat — and Improved Sleep — Without Lean-Mass Loss: What the Pep19 Trial Shows, and How It Differs From GLP-1s — June 13, 2026

](/blog/pep19-endocannabinoid-peptide-visceral-fat-sleep-vs-glp1-june-13-2026)

An early human trial of Pep19 — a synthetic intracellular peptide that works through the endocannabinoid system — cut visceral fat by about 17% and improved sleep over 60 days, with no lean-mass loss and no reported side effects. That combination is unusual. Here's what the data actually show, why the endocannabinoid mechanism is both promising and historically fraught, and how Pep19 differs from the GLP-1 and amylin drugs dominating the obesity conversation.

PepTracker Pro Team 

June 13, 2026  9 min read 

Pep19endocannabinoid peptideendocannabinoid system

[Read](/blog/pep19-endocannabinoid-peptide-visceral-fat-sleep-vs-glp1-june-13-2026)

[![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/exercise-mimetic-research-compounds-mainstream-slu-pp-332-5-amino-1mq-mots-c-pcac-june-12-2026)

Research & Compounds [

### 'Exercise in a Pill' Goes Mainstream: SLU-PP-332, 5-Amino-1MQ, and MOTS-c — and Why the FDA's July PCAC Vote Won't Cover All of Them — June 12, 2026

](/blog/exercise-mimetic-research-compounds-mainstream-slu-pp-332-5-amino-1mq-mots-c-pcac-june-12-2026)

A wave of 'exercise mimetic' and mitochondrial metabolic compounds — SLU-PP-332, 5-Amino-1MQ, and MOTS-c — is moving from research-chemical forums into mainstream wellness, with anti-doping labs now building detection assays. But there's a critical distinction buyers miss: only some of these are on the FDA's July 23–24 PCAC compounding review list. We break down the mechanisms, the evidence (almost entirely preclinical), and what the July vote actually changes.

PepTracker Pro Team 

June 12, 2026  9 min read 

SLU-PP-332exercise mimeticERR agonist

[Read](/blog/exercise-mimetic-research-compounds-mainstream-slu-pp-332-5-amino-1mq-mots-c-pcac-june-12-2026)

[![Policy & Pipeline cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/telehealth-peptide-vertical-integration-noom-tailor-made-hims-eloralintide-tirzepatide-pcac-june-11-2026)

Policy & Pipeline [

### Telehealth Goes Vertical on Peptides: Noom Acquires Tailor Made Compounding, Hims & Hers Expands Production, and Eloralintide's Combination Era Begins — June 11, 2026

](/blog/telehealth-peptide-vertical-integration-noom-tailor-made-hims-eloralintide-tirzepatide-pcac-june-11-2026)

Telehealth platforms are racing to own regulated peptide supply chains ahead of the FDA's July 23–24 PCAC vote. Noom has acquired 503A pharmacy Tailor Made Compounding to add sermorelin and NAD+ to its formulary, following Hims & Hers' peptide facility purchase. Meanwhile, Eli Lilly's selective amylin agonist eloralintide enters its combination era with a tirzepatide pairing trial reading out late 2026.

PepTracker Pro Team 

June 11, 2026  10 min read 

noomtailor made compoundinghims and hers

[Read](/blog/telehealth-peptide-vertical-integration-noom-tailor-made-hims-eloralintide-tirzepatide-pcac-june-11-2026)

[![Policy & Pipeline cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/medicare-glp1-bridge-july-2026-cagrisema-review-retatrutide-nda-pcac-countdown-june-10-2026)

Policy & Pipeline [

### Medicare GLP-1 Bridge Launches July 1 at $50/Month for Wegovy, Zepbound, and Foundayo — Plus CagriSema FDA Review Update, Retatrutide NDA Timeline, and PCAC July 23–24 Countdown — June 10, 2026

](/blog/medicare-glp1-bridge-july-2026-cagrisema-review-retatrutide-nda-pcac-countdown-june-10-2026)

CMS's Medicare GLP-1 Bridge launches July 1, 2026, capping Wegovy, Zepbound, and Foundayo at $50/month for Medicare Part D beneficiaries — the most significant GLP-1 access expansion to date. We also track CagriSema's FDA review timeline, Eli Lilly's retatrutide NDA preparation for Q4 2026, and the approaching July 23–24 PCAC vote on BPC-157 and six other research peptides.

PepTracker Pro Team 

June 10, 2026  11 min read 

medicareGLP-1semaglutide

[Read](/blog/medicare-glp1-bridge-july-2026-cagrisema-review-retatrutide-nda-pcac-countdown-june-10-2026)

[![research-summaries cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/post-ada-2026-synthesis-aleniglipron-nature-medicine-wegovy-pill-3million-cvs-pcac-july-bpc157-june-9-2026)

research-summaries [

### Post-ADA 2026 Synthesis: Aleniglipron Phase 2b Published in Nature Medicine, Wegovy Pill Surpasses 3 Million Prescriptions, CVS Caremark Resets GLP-1 Formulary, and PCAC July 23–24 Review of BPC-157, TB-500, and Five Research Peptides Approaches — June 9, 2026

](/blog/post-ada-2026-synthesis-aleniglipron-nature-medicine-wegovy-pill-3million-cvs-pcac-july-bpc157-june-9-2026)

The close of ADA 2026 triggered a cluster of significant developments: Structure Therapeutics published the aleniglipron ACCESS Phase 2b results in Nature Medicine on June 5 — the first peer-reviewed full-data paper for an oral non-peptide GLP-1 RA in a major journal. Novo Nordisk announced that oral semaglutide (Wegovy pill) has surpassed 3 million prescriptions in five months. CVS Caremark announced a formulary reset that places Foundayo (orforglipron) and Zepbound on equal footing with Wegovy, reshaping the commercial GLP-1 landscape. And the FDA's Pharmacy Compounding Advisory Committee will meet July 23–24, 2026 to vote on whether BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, and DSIP can be legally compounded — a pivotal regulatory moment for research peptides.

Helix Horizon Research Team 

June 9, 2026  10 min read min read 

ADA-2026aleniglipronGSBR-1290

[Read](/blog/post-ada-2026-synthesis-aleniglipron-nature-medicine-wegovy-pill-3million-cvs-pcac-july-bpc157-june-9-2026)

[![research-summaries cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/ada-2026-day4-berobenatide-monthly-glp1-orforglipron-menopause-asc30-oral-june-8-2026)

research-summaries [

### ADA 2026 Final Day: Pfizer's Berobenatide Delivers 12.3% Weight Loss as First Monthly GLP-1 RA, Orforglipron Shows Significant Weight Loss Across All Menopause Stages, ASC30 Oral GLP-1 Posts 7.7% Weight Loss at 13 Weeks — June 8, 2026 Peptide Research Update

](/blog/ada-2026-day4-berobenatide-monthly-glp1-orforglipron-menopause-asc30-oral-june-8-2026)

ADA 2026 closes with three major findings: Pfizer's berobenatide delivers 12.3% placebo-adjusted weight loss with once-monthly injection — potentially the first monthly GLP-1 RA to reach Phase 3. Orforglipron (Foundayo) shows up to 30.4 lbs weight loss across all menopause stages in ATTAIN sub-analyses, and ACHIEVE-2/-5 confirm T2D superiority. Ascletis's ASC30 oral GLP-1 posts 7.7% placebo-adjusted weight loss at 13 weeks with 2–3x greater in vitro potency than orforglipron.

Helix Horizon Research Team 

June 8, 2026  11 min read min read 

ADA-2026berobenatidePfizer

[Read](/blog/ada-2026-day4-berobenatide-monthly-glp1-orforglipron-menopause-asc30-oral-june-8-2026)

[![research-summaries cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/ada-2026-day3-triumph4-retatrutide-osteoarthritis-zenagamtide-t2d-cagrIsema-brain-june-2026)

research-summaries [

### ADA 2026 Day 3: Retatrutide TRIUMPH-4 Sets 28.7% Weight Loss Record With 75.8% Knee Pain Relief, Zenagamtide Delivers 14.6% Weight Loss and 89% A1C Target in Type 2 Diabetes Phase 2, CagriSema Brain Activity Data Reveals Appetite-Circuit Mechanism — June 7, 2026 Peptide Research Update

](/blog/ada-2026-day3-triumph4-retatrutide-osteoarthritis-zenagamtide-t2d-cagrIsema-brain-june-2026)

ADA 2026 Day 3: Retatrutide TRIUMPH-4 shows 28.7% weight loss plus 75.8% WOMAC knee pain reduction — highest pain relief in any obesity-OA drug trial. Zenagamtide (amycretin) posts 14.6% weight loss and 89% A1C target achievement in Phase 2 T2D, triggering Phase 3 T2D program for H2 2026. CagriSema functional brain imaging reveals the amylin+GLP-1 appetite-circuit mechanism behind its 22.7% weight loss.

Helix Horizon Research Team 

June 7, 2026  12 min read min read 

ADA-2026retatrutideTRIUMPH-4

[Read](/blog/ada-2026-day3-triumph4-retatrutide-osteoarthritis-zenagamtide-t2d-cagrIsema-brain-june-2026)

[![research-summaries cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/ada-2026-day2-petrelintide-zupreme1-full-data-da1726-posters-amylin-metabolic-june-2026)

research-summaries [

### ADA 2026 Day 2: Petrelintide Full ZUPREME-1 Data Confirms Cardiometabolic Benefits and Phase 3 Path, DA-1726 Posts Three Abstracts — June 6, 2026 Peptide Research Update

](/blog/ada-2026-day2-petrelintide-zupreme1-full-data-da1726-posters-amylin-metabolic-june-2026)

ADA 2026 Day 2 in New Orleans brings full ZUPREME-1 body composition and cardiometabolic data for petrelintide (Zealand/Roche) — confirming hsCRP reductions of 17–41%, triglyceride reductions of 12–21%, and waist circumference improvements of up to 10.8 cm, all with placebo-like tolerability — alongside three MetaVia DA-1726 late-breaking poster abstracts covering final MAD data, lean mass preservation, and direct hepatic FibroScan endpoints.

PepTracker Pro Research Team 

June 6, 2026  8 min read min read 

ADA-2026ADA-Scientific-SessionsNew-Orleans

[Read](/blog/ada-2026-day2-petrelintide-zupreme1-full-data-da1726-posters-amylin-metabolic-june-2026)

[![research-summaries cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/ada-2026-opens-retatrutide-triumph1-survodutide-synchronize1-cagrisema-reimagine-zenagamtide-june-2026)

research-summaries [

### ADA 2026 Opens in New Orleans: Retatrutide TRIUMPH-1 Full Data, Survodutide SYNCHRONIZE-1 Confirmation, CagriSema REIMAGINE 1–3 Symposium, and Zenagamtide Phase 2 — June 5, 2026 Peptide Research Update

](/blog/ada-2026-opens-retatrutide-triumph1-survodutide-synchronize1-cagrisema-reimagine-zenagamtide-june-2026)

The ADA 2026 Scientific Sessions open today in New Orleans (June 5–8) with an unprecedented density of late-stage obesity and diabetes pipeline data: Eli Lilly presents full TRIUMPH-1 retatrutide data (28.3% weight loss, 80 wks), Boehringer Ingelheim presents complete SYNCHRONIZE-1 survodutide results (16.6% vs 3.2% placebo, 76 wks), Novo Nordisk hosts a REIMAGINE 1–3 symposium for CagriSema in T2D, and presents zenagamtide Phase 2 data (up to 24.3% weight loss) as its next-generation GLP-1/amylin molecule.

PepTracker Pro Research Team 

June 5, 2026  10 min read min read 

ADA-2026ADA-Scientific-SessionsNew-Orleans

[Read](/blog/ada-2026-opens-retatrutide-triumph1-survodutide-synchronize1-cagrisema-reimagine-zenagamtide-june-2026)

[![research-summaries cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/enicepatide-ct388-biased-glp1-gip-agonist-phase2-22-percent-weight-loss-ada-2026-june-2026)

research-summaries [

### Enicepatide (CT-388) Posts ~22.5% Weight Loss in Phase 2 and Heads to ADA 2026: Roche's Signal-Biased GLP-1/GIP Agonist - June 4, 2026 Peptide Research Update

](/blog/enicepatide-ct388-biased-glp1-gip-agonist-phase2-22-percent-weight-loss-ada-2026-june-2026)

Roche and Genentech's investigational dual GLP-1/GIP receptor agonist enicepatide (CT-388) delivered up to ~22.5% placebo-adjusted weight loss at 48 weeks in its Phase 2 trial - among the largest incretin results to date - and presents late-breaking data at ADA 2026 as it advances to Phase 3 and toward a fixed-dose combination with petrelintide.

PepTracker Pro Research Team 

June 4, 2026  8 min read min read 

enicepatideCT-388RO7795068

[Read](/blog/enicepatide-ct388-biased-glp1-gip-agonist-phase2-22-percent-weight-loss-ada-2026-june-2026)

[![research-summaries cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/petrelintide-amylin-phase2-zupreme-1-tolerability-roche-zealand-ada-2026-june-2026)

research-summaries [

### Petrelintide and the Amylin Moment: Zealand and Roche's Phase 2 Win on Tolerability Heads to ADA 2026 — June 1, 2026 Peptide Research Update

](/blog/petrelintide-amylin-phase2-zupreme-1-tolerability-roche-zealand-ada-2026-june-2026)

Zealand Pharma and Roche's amylin analog petrelintide delivered up to 10.7% mean weight loss in the Phase 2 ZUPREME-1 trial with GI side effects comparable to placebo - a tolerability-first profile heading to ADA 2026 as the amylin class matures into the next pillar of obesity care.

PepTracker Pro Research Team 

June 1, 2026  8 min read min read 

petrelintideZP8396amylin

[Read](/blog/petrelintide-amylin-phase2-zupreme-1-tolerability-roche-zealand-ada-2026-june-2026)

[![research-summaries cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/alv-100-alveus-gipr-antagonist-glp1-amycretin-phase2-ada-2026-imminent-may-2026)

research-summaries [

### ALV-100 and the Rise of Well-Financed GIPR-Antagonist + GLP-1 Obesity Peptides: Alveus Enters the Clinic, Amycretin's Phase 2 Detail, and the Imminent ADA 2026 Catalyst — May 31, 2026 Peptide Research Update

](/blog/alv-100-alveus-gipr-antagonist-glp1-amycretin-phase2-ada-2026-imminent-may-2026)

Alveus Therapeutics' ALV-100, a bifunctional GIPR-antagonist / GLP-1-agonist peptide, has entered a Phase 1b obesity trial backed by a ~$197M Series A, joining the MariTide-style combination class focused on the quality and durability of weight loss; meanwhile amycretin's Phase 2 detail (11.9% placebo-adjusted weekly subcutaneous weight loss) heads toward Phase 3 and the ADA 2026 Scientific Sessions (June 5-8, New Orleans) prepares to release late-breaking obesity data on June 5.

PepTracker Pro Research Team 

May 31, 2026  8 min read min read 

ALV-100Alveus-TherapeuticsALV-200

[Read](/blog/alv-100-alveus-gipr-antagonist-glp1-amycretin-phase2-ada-2026-imminent-may-2026)

[![research-summaries cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/gipr-antagonism-at7687-ada-2026-preview-retatrutide-triumph-survodutide-eloralintide-may-2026)

research-summaries [

### GIPR Antagonism Emerges as a New Obesity Class: AT7687 Heads to ADA 2026 Alongside Retatrutide TRIUMPH-1 30% Data, Survodutide SYNCHRONIZE-1, and Eloralintide's Published Phase 1 — May 30, 2026 Peptide Research Update

](/blog/gipr-antagonism-at7687-ada-2026-preview-retatrutide-triumph-survodutide-eloralintide-may-2026)

AT7687, a first-in-class GIPR antagonist, heads to ADA 2026 after Phase 1 tolerability and amylin-combination data, spotlighting GIPR antagonism as an emerging obesity class; retatrutide TRIUMPH-1 reaches up to 30.3% weight loss, survodutide SYNCHRONIZE-1 confirms 16.6%, and eloralintide's Phase 1 proof of concept is published in DOM ahead of the June 5-8 ADA Scientific Sessions.

PepTracker Pro Research Team 

May 30, 2026  8 min read min read 

AT7687Antag-TherapeuticsGIPR

[Read](/blog/gipr-antagonism-at7687-ada-2026-preview-retatrutide-triumph-survodutide-eloralintide-may-2026)

[![research-summaries cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/da-1726-easl-liver-23andme-glp1-pharmacogenomics-pcac-bpc157-orforglipron-may-2026)

research-summaries [

### DA-1726 EASL Liver Data Bolsters Dual Obesity-MASH Positioning, 23andMe Nature Study Maps GLP-1 Pharmacogenomics for 27,885 Users, FDA PCAC July Review of BPC-157 TB-500 KPV Approaches, and Orforglipron Foundayo Reshapes Oral GLP-1 Access — May 29, 2026 Peptide Research Update

](/blog/da-1726-easl-liver-23andme-glp1-pharmacogenomics-pcac-bpc157-orforglipron-may-2026)

DA-1726 presents EASL 2026 FibroScan liver data showing CAP and stiffness improvements alongside 9.1% weight loss, a 23andMe Nature study identifies GLP1R and GIPR variants predicting GLP-1 drug response in 27,885 users, FDA PCAC July 23-24 review of BPC-157/TB-500/KPV/MOTS-c approaches after HHS Category 2 removal, and orforglipron Foundayo reshapes oral GLP-1 access post-FDA approval.

PepTracker Pro Research Team 

May 29, 2026  8 min read min read 

DA-1726MetaViaEASL-2026

[Read](/blog/da-1726-easl-liver-23andme-glp1-pharmacogenomics-pcac-bpc157-orforglipron-may-2026)

[![research-summaries cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/easl-2026-pemvidutide-bimagrumab-muscle-preservation-retatrutide-nda-taldefgrobep-glp1-compounding-may-2026)

research-summaries [

### EASL 2026 Crowns Pemvidutide Best of Congress for MASH Fibrosis Regression, Bimagrumab + Semaglutide Redefines Muscle-Preserving Weight Loss in Nature Medicine, Retatrutide NDA on Track After TRIUMPH-1, Taldefgrobep Enters Obesity Arena, and FDA GLP-1 Compounding Comment Period Closes June 29 — May 28, 2026 Peptide Research Update

](/blog/easl-2026-pemvidutide-bimagrumab-muscle-preservation-retatrutide-nda-taldefgrobep-glp1-compounding-may-2026)

EASL 2026 names pemvidutide IMPACT data Best of Congress with 68.6% qFibrosis regression, the BELIEVE trial in Nature Medicine shows bimagrumab + semaglutide achieves 22.1% weight loss with 92% from fat, retatrutide TRIUMPH-1 sets 28.3% weight loss record and NDA filing on track for Q4 2026, Biohaven's taldefgrobep completes Phase 2 enrollment for muscle-preserving obesity treatment, and FDA's GLP-1 compounding exclusion comment period closes June 29.

Helix Horizon Research Team 

May 28, 2026  12 min read min read 

EASL-2026pemvidutideMASH

[Read](/blog/easl-2026-pemvidutide-bimagrumab-muscle-preservation-retatrutide-nda-taldefgrobep-glp1-compounding-may-2026)

[![research-summaries cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/ada-2026-preview-da-1726-glp1-neuroprotection-dementia-compounding-market-sermorelin-tirzepatide-mash-may-2026)

research-summaries [

### ADA 2026 Preview: DA-1726 Earns Three Late-Breaking Posters, GLP-1 Neuroprotection Data Links Semaglutide to 35% Lower Dementia Risk, FDA Peptide Compounding Market Attracts Startup Investment, Sermorelin Reinstated to Category 1, and Tirzepatide MASH Approval Reshapes Liver Disease Treatment — May 27, 2026 Peptide Research Update

](/blog/ada-2026-preview-da-1726-glp1-neuroprotection-dementia-compounding-market-sermorelin-tirzepatide-mash-may-2026)

ADA 2026 approaches with DA-1726 earning three late-breaking posters, real-world data links GLP-1 agonists to 20-35% lower dementia risk with semaglutide showing the strongest effect, FDA compounding market attracts startup investment ahead of PCAC July meeting, sermorelin officially reinstated to Category 1, and tirzepatide MASH approval marks second incretin therapy for liver disease.

Helix Horizon Research Team 

May 27, 2026  11 min read min read 

ADA-2026DA-1726MetaVia

[Read](/blog/ada-2026-preview-da-1726-glp1-neuroprotection-dementia-compounding-market-sermorelin-tirzepatide-mash-may-2026)

[![News & Updates cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/maritide-maritime-phase3-pfizer-obesity-trials-ava6103-pdc-glp1-cv-meta-analysis-triumph2-may-26-2026)

News & Updates [

### MariTide Phase 3 MARITIME Program Advances With Quarterly Dosing Data, Pfizer Plans 20+ Obesity Trials for 2026, AVA6103 FAP-Targeted PDC Enters Phase 1 for Solid Tumors, GLP-1 CV Meta-Analysis Covers 99,599 Patients, and TRIUMPH-2 Readout Looms as Next Major Catalyst — May 26, 2026 Peptide Research Update

](/blog/maritide-maritime-phase3-pfizer-obesity-trials-ava6103-pdc-glp1-cv-meta-analysis-triumph2-may-26-2026)

Amgen's MariTide Phase 3 MARITIME program advances across six indications with Phase 2 maintenance data showing sustained weight loss on quarterly dosing. Pfizer outlines an unprecedented 20+ obesity trial program for 2026 with ADA data imminent. AVA6103 becomes the first FAP-targeted sustained-release PDC to enter clinical trials for solid tumors. A landmark JACC meta-analysis of 99,599 patients confirms GLP-1 drugs slash cardiovascular events across all demographics. Plus: TRIUMPH-2 diabetes readout approaches as next major industry catalyst.

PepTracker Pro Team 

May 26, 2026  10 min read 

MariTidemaridebart-cafraglutideAmgen

[Read](/blog/maritide-maritime-phase3-pfizer-obesity-trials-ava6103-pdc-glp1-cv-meta-analysis-triumph2-may-26-2026)

[![News & Updates cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/triumph1-record-glp1-cv-meta-analysis-oral-ozempic-launch-peptide-market-growth-may-2026)

News & Updates [

### TRIUMPH-1 Shatters Weight Loss Records at 30.3%, GLP-1 CV Meta-Analysis Confirms Heart Protection Across 90,000 Patients, Oral Ozempic Launches Nationwide, and Peptide Market Poised for Explosive Growth — May 25, 2026 Peptide Research Update

](/blog/triumph1-record-glp1-cv-meta-analysis-oral-ozempic-launch-peptide-market-growth-may-2026)

Retatrutide TRIUMPH-1 delivers 28.3% weight loss at 80 weeks and 30.3% at 104 weeks — the largest ever recorded in a Phase 3 obesity trial. A landmark meta-analysis of 90,000+ patients confirms GLP-1 drugs slash heart attacks, strokes, and cardiovascular death. Oral Ozempic tablets launch nationwide at $149/month. The global peptide-based health market is forecast for explosive long-term growth. Plus: AI peptide design competition unites 300 researchers, and the PCAC July countdown continues.

PepTracker Pro Team 

May 25, 2026  10 min read 

retatrutideTRIUMPH-1Eli-Lilly

[Read](/blog/triumph1-record-glp1-cv-meta-analysis-oral-ozempic-launch-peptide-market-growth-may-2026)

[![News & Updates cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/da-1726-phase-1-cotadutide-mash-pemvidutide-phase-3-glp1-glucagon-dual-agonist-report-may-2026)

News & Updates [

### DA-1726 Phase 1 Stuns With 9.1% Weight Loss in 8 Weeks, Cotadutide MASH Data Shapes Dual Agonist Landscape, Pemvidutide Phase 3 Initiation Planned — GLP-1/Glucagon Dual Agonist Special Report, May 2026

](/blog/da-1726-phase-1-cotadutide-mash-pemvidutide-phase-3-glp1-glucagon-dual-agonist-report-may-2026)

DA-1726 delivers 9.1% weight loss in just 8 weeks in Phase 1, challenging early-phase benchmarks. Cotadutide's MASH trial data establishes the dual agonist mechanistic template. Pemvidutide secures FDA Breakthrough Therapy Designation with Phase 3 initiation planned. Over 100 GLP-1-based compounds now in development as dual agonism emerges as the dominant next-generation strategy.

PepTracker Pro Team 

May 22, 2026  9 min read 

DA-1726MetaViacotadutide

[Read](/blog/da-1726-phase-1-cotadutide-mash-pemvidutide-phase-3-glp1-glucagon-dual-agonist-report-may-2026)

[![News & Updates cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/aleniglipron-access-ii-44w-cagrisema-reimagine-2-triumph-1-readout-peptide-market-growth-may-2026)

News & Updates [

### Aleniglipron Tops Oral GLP-1 Efficacy, CagriSema REIMAGINE-2 Adds T2D Data, TRIUMPH-1 Readout Looms — Week of May 20, 2026

](/blog/aleniglipron-access-ii-44w-cagrisema-reimagine-2-triumph-1-readout-peptide-market-growth-may-2026)

Aleniglipron ACCESS II 44-week data sets new oral GLP-1 efficacy record at 16.3% weight loss with FDA Phase 3 green light. CagriSema REIMAGINE 2 confirms dual-pathway superiority over semaglutide in type 2 diabetes. TRIUMPH-1 retatrutide readout imminent with 30%+ weight loss projected. Global peptide market forecast to reach $11.2B by 2035 as AI compresses discovery timelines.

PepTracker Pro Team 

May 20, 2026  10 min read 

aleniglipronGSBR-1290Structure-Therapeutics

[Read](/blog/aleniglipron-access-ii-44w-cagrisema-reimagine-2-triumph-1-readout-peptide-market-growth-may-2026)

[![News & Updates cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/navepegritide-fda-approval-retatrutide-transcend-tesamorelin-meta-analysis-pcac-countdown-may-2026)

News & Updates [

### Navepegritide FDA Approval, Retatrutide TRANSCEND-T2D-1, Tesamorelin Meta-Analysis, and PCAC Countdown — Week of May 19, 2026

](/blog/navepegritide-fda-approval-retatrutide-transcend-tesamorelin-meta-analysis-pcac-countdown-may-2026)

Navepegritide (Yuviwel) becomes the first once-weekly CNP analog FDA-approved for achondroplasia in children. Retatrutide TRANSCEND-T2D-1 reports 2.0% A1C reduction and 16.8% weight loss. New tesamorelin meta-analysis confirms targeted visceral fat reduction. PCAC July 23–24 meeting approaches with public comment deadline July 9 for BPC-157, TB-500, KPV, and MOTS-c.

PepTracker Pro Team 

May 19, 2026  9 min read 

navepegritideYuviwelachondroplasia

[Read](/blog/navepegritide-fda-approval-retatrutide-transcend-tesamorelin-meta-analysis-pcac-countdown-may-2026)

[![News & Updates cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/vk2735-oral-eco-2026-retatrutide-triumph-1-ai-antimicrobial-peptides-oral-wegovy-uptake-pdc-cancer-may-2026)

News & Updates [

### VK2735 Oral Achieves 12.2% Weight Loss at ECO 2026 With Maintenance Data, Retatrutide TRIUMPH-1 Pivotal Readout Imminent With 30%+ Projections, AI Antimicrobial Peptides Hit 79% Success Rate, Oral Wegovy Shows Rapid Real-World Uptake, and Peptide-Drug Conjugates Advance Cancer Precision Delivery — May 18, 2026 Peptide Research Update

](/blog/vk2735-oral-eco-2026-retatrutide-triumph-1-ai-antimicrobial-peptides-oral-wegovy-uptake-pdc-cancer-may-2026)

Viking's oral VK2735 achieves 12.2% weight loss at 13 weeks with novel maintenance data at ECO 2026. Retatrutide TRIUMPH-1 pivotal readout due Q2–Q3 2026 with analyst projections above 30%. AI-discovered antimicrobial peptides deliver 79% hit rate from 863K candidate sequences. Oral Wegovy sees rapid real-world adoption with 36% new-to-GLP-1 patients. Peptide-drug conjugates achieve 85% tumor-specific delivery in Phase II.

PepTracker Pro Team 

May 18, 2026  10 min read 

VK2735Viking-TherapeuticsVENTURE-Oral

[Read](/blog/vk2735-oral-eco-2026-retatrutide-triumph-1-ai-antimicrobial-peptides-oral-wegovy-uptake-pdc-cancer-may-2026)

[![News & Updates cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/brp-natural-ozempic-quintuple-agonist-cagrisema-nejm-ptp-r-oral-semaglutide-obesity-may-2026)

News & Updates [

### Stanford's BRP Peptide Offers 'Natural Ozempic' Without GI Side Effects, Quintuple Agonist Hits 5 Targets in One Molecule, CagriSema Achieves 20.4% Weight Loss in NEJM, PTP-r Destroys Fat Cells Via Mitochondrial Targeting, and Oral Semaglutide Gets Historic Obesity Approval — May 16, 2026 Peptide Research Update

](/blog/brp-natural-ozempic-quintuple-agonist-cagrisema-nejm-ptp-r-oral-semaglutide-obesity-may-2026)

Stanford's AI-discovered BRP peptide suppresses appetite via hypothalamus without GLP-1 side effects. A Nature-published quintuple agonist targets 5 receptors simultaneously. CagriSema delivers 20.4% weight loss in pivotal NEJM trial. Queensland's PTP-r destroys white fat cells through mitochondrial disruption. FDA approves first-ever oral GLP-1 pill for obesity ($149/month).

PepTracker Pro Team 

May 16, 2026  11 min read 

BRPBRINP2Stanford

[Read](/blog/brp-natural-ozempic-quintuple-agonist-cagrisema-nejm-ptp-r-oral-semaglutide-obesity-may-2026)

[![News & Updates cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/mbx-4291-phase-1-mbx-5765-quad-agonist-asc47-eco-2026-bi-3034701-phase-2-gep-44-may-2026)

News & Updates [

### MBX 4291 Delivers 7% Weight Loss at 8 Weeks With Near-Zero GI Side Effects, MBX 5765 Quad Agonist Nominated, ECO 2026 Showcases ASC47 Muscle-Preserving Combo, BI 3034701 Enters Phase 2, and GEP-44 Triple Agonist Advances — May 12, 2026 Peptide Research Update

](/blog/mbx-4291-phase-1-mbx-5765-quad-agonist-asc47-eco-2026-bi-3034701-phase-2-gep-44-may-2026)

MBX Biosciences reports Phase 1 data showing 7% mean weight loss at 8 weeks for MBX 4291 with only 1 mild GI event and zero nausea or vomiting, plus nominates MBX 5765 as first-ever GLP-1/GIP/GCG/DACRA quad agonist. ECO 2026 features ASC47 data showing 111.8% greater weight loss when added to semaglutide. Boehringer Ingelheim advances BI 3034701 (GLP-1/GIP/NPY2 triple agonist) to Phase 2. GEP-44 triple agonist targeting GLP-1/PYY-Y1/PYY-Y2 progresses through IND-enabling studies.

PepTracker Pro Team 

May 12, 2026  9 min read 

MBX-4291MBX-BiosciencesMBX-5765

[Read](/blog/mbx-4291-phase-1-mbx-5765-quad-agonist-asc47-eco-2026-bi-3034701-phase-2-gep-44-may-2026)

[![News & Updates cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/cagrisema-redefine-4-glp1-depression-oral-brain-cravings-eco-2026-istanbul-may-2026)

News & Updates [

### CagriSema Falls Short vs Tirzepatide in REDEFINE 4, GLP-1 Drugs Linked to 42% Lower Depression Risk, NIH Reveals How Oral GLP-1s Suppress Cravings Deep in the Brain, and ECO 2026 Kicks Off in Istanbul — May 11, 2026 Peptide Research Update

](/blog/cagrisema-redefine-4-glp1-depression-oral-brain-cravings-eco-2026-istanbul-may-2026)

CagriSema achieves 23% weight loss but fails to match tirzepatide in head-to-head REDEFINE 4 trial. A landmark Lancet Psychiatry study links GLP-1 drugs to a 42% lower risk of worsening depression and anxiety. NIH-funded Nature paper reveals oral GLP-1 drugs suppress cravings by reaching the brain's central amygdala. ECO 2026 opens in Istanbul with Ascletis monthly peptide data and VK2735 oral presentations. PCAC July 2026 agenda confirmed for BPC-157, TB-500, KPV, and MOTS-c.

PepTracker Pro Team 

May 11, 2026  10 min read 

CagriSemaREDEFINE-4Novo-Nordisk

[Read](/blog/cagrisema-redefine-4-glp1-depression-oral-brain-cravings-eco-2026-istanbul-may-2026)

[![News & Updates cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/synchronize-1-results-eco-2026-monthly-peptides-fda-503b-glp1-gip-glucagon-may-2026)

News & Updates [

### SYNCHRONIZE-1 Delivers 16.6% Weight Loss, ECO 2026 Showcases Monthly Peptides, FDA Moves to Block Compounded GLP-1s, and GIP/Glucagon Research Challenges GLP-1 Necessity — May 9, 2026 Peptide Research Update

](/blog/synchronize-1-results-eco-2026-monthly-peptides-fda-503b-glp1-gip-glucagon-may-2026)

Survodutide SYNCHRONIZE-1 Phase 3 reports 16.6% weight loss at 76 weeks. ECO 2026 in Istanbul features Viking's VK2735 oral data and Ascletis's once-monthly ASC36/ASC35/ASC37 pipeline. The FDA proposes permanently excluding semaglutide, tirzepatide, and liraglutide from 503B compounding. And a Molecular Metabolism paper shows GIP/glucagon dual agonism achieves weight loss without GLP-1 — potentially eliminating GI side effects.

PepTracker Pro Team 

May 9, 2026  9 min read 

survodutideSYNCHRONIZE-1Boehringer-Ingelheim

[Read](/blog/synchronize-1-results-eco-2026-monthly-peptides-fda-503b-glp1-gip-glucagon-may-2026)

[![News & Updates cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/fda-pcac-july-peptides-tirzepatide-semaglutide-nejm-vk2735-vanquish-cap-gdf15-may-2026)

News & Updates [

### FDA PCAC July Lineup Confirmed for 7 Peptides, Tirzepatide Beats Semaglutide in NEJM Head-to-Head, VK2735 VANQUISH-2 Enrollment Completes, and CAP-GDF15 Opens New Appetite Pathway — May 8, 2026 Peptide Research Update

](/blog/fda-pcac-july-peptides-tirzepatide-semaglutide-nejm-vk2735-vanquish-cap-gdf15-may-2026)

The FDA confirms its July 23–24 PCAC meeting will review BPC-157, TB-500, KPV, MOTS-c, Semax, Epithalon, and DSIP for 503A compounding eligibility. A landmark NEJM trial shows tirzepatide outperforms semaglutide by 6.5 percentage points in weight loss. Viking completes VANQUISH-2 enrollment for VK2735, and researchers identify CAP-GDF15 as a new appetite-suppressing peptide from the GDF15 propeptide region.

PepTracker Pro Team 

May 8, 2026  8 min read 

FDAPCACBPC-157

[Read](/blog/fda-pcac-july-peptides-tirzepatide-semaglutide-nejm-vk2735-vanquish-cap-gdf15-may-2026)

[![News & Updates cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/aleniglipron-oral-glp1-retatrutide-triumph1-pemvidutide-lancet-ai-antimicrobial-peptides-may-2026)

News & Updates [

### Aleniglipron Joins the Oral GLP-1 Race, Retatrutide TRIUMPH-1 Readout Imminent, Pemvidutide Lancet Publication, and AI-Designed Antimicrobial Peptides Enter Early Trials — May 7, 2026 Peptide Research Update

](/blog/aleniglipron-oral-glp1-retatrutide-triumph1-pemvidutide-lancet-ai-antimicrobial-peptides-may-2026)

Structure Therapeutics' aleniglipron posts up to 15.3% weight loss in Phase 2, readying Phase 3 to compete with Foundayo. Retatrutide's pivotal TRIUMPH-1 obesity readout is expected any day. Pemvidutide's MASH data reaches The Lancet with Breakthrough Therapy Designation. And AI-designed antimicrobial peptides advance toward clinics.

PepTracker Pro Team 

May 7, 2026  7 min read 

aleniglipronGSBR-1290oral-GLP-1

[Read](/blog/aleniglipron-oral-glp1-retatrutide-triumph1-pemvidutide-lancet-ai-antimicrobial-peptides-may-2026)

[![News & Updates cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/icotrokinra-oral-peptide-ecnoglutide-china-foxo4dri-senolytic-amycretin-phase3-may-2026)

News & Updates [

### Icotrokinra Makes Oral Peptide History, Ecnoglutide Approved in China, FOXO4-DRI Senolytic Research Advances, and Amycretin Phase 3 Begins — May 6, 2026 Peptide Research Update

](/blog/icotrokinra-oral-peptide-ecnoglutide-china-foxo4dri-senolytic-amycretin-phase3-may-2026)

FDA approves the first oral macrocyclic peptide (icotrokinra) for psoriasis, China greenlights the world's first cAMP-biased GLP-1 RA (ecnoglutide) for weight management, FOXO4-DRI senolytic peptide research expands to human chondrocyte models, and Novo Nordisk launches Phase 3 for amycretin's dual GLP-1/amylin agonism.

PepTracker Pro Team 

May 6, 2026  8 min read 

icotrokinraICOTYDEmacrocyclic-peptide

[Read](/blog/icotrokinra-oral-peptide-ecnoglutide-china-foxo4dri-senolytic-amycretin-phase3-may-2026)

[![News & Updates cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/quintuple-agonist-nature-gdf15-apelin-cardiovascular-peptide-pipeline-may-2026)

News & Updates [

### Nature Publishes First Quintuple Agonist for Obesity, GDF-15 Emerges as Non-GLP-1 Alternative, Apelin Advances in Cardioprotection — May 2026 Peptide Pipeline Update

](/blog/quintuple-agonist-nature-gdf15-apelin-cardiovascular-peptide-pipeline-may-2026)

A landmark Nature paper introduces the first quintuple receptor agonist (GLP-1/GIP/PPARα/γ/δ) for obesity, GDF-15 receptor agonists gain momentum as a non-GLP-1 weight loss mechanism, and apelin/APJ cardiovascular peptides advance toward clinical candidates.

PepTracker Pro Team 

May 5, 2026  7 min read 

quintuple-agonistGLP-1GIP

[Read](/blog/quintuple-agonist-nature-gdf15-apelin-cardiovascular-peptide-pipeline-may-2026)

[![News & Updates cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/semaglutide-evoke-alzheimers-failure-vk2735-vanquish2-bpc157-pcac-docket-caqk-tbi-may-2026)

News & Updates [

### Semaglutide EVOKE Alzheimer's Trials Fail on Cognition, VK2735 VANQUISH-2 Fully Enrolled, BPC-157 PCAC Docket Opens, and CAQK Nears Human Trials — May 2026 Peptide Research Update

](/blog/semaglutide-evoke-alzheimers-failure-vk2735-vanquish2-bpc157-pcac-docket-caqk-tbi-may-2026)

Semaglutide's EVOKE/EVOKE+ Alzheimer's trials show no cognitive benefit at 104 weeks despite reducing CSF p-tau181, Viking Therapeutics completes VANQUISH-2 Phase 3 enrollment for VK2735, the FDA opens the BPC-157 public comment docket ahead of the July 23 PCAC meeting, and Aivocode's CAQK peptide prepares for its first human trial after definitive preclinical TBI data.

PepTracker Pro Team 

May 4, 2026  8 min read 

semaglutidealzheimersevoke

[Read](/blog/semaglutide-evoke-alzheimers-failure-vk2735-vanquish2-bpc157-pcac-docket-caqk-tbi-may-2026)

[![News & Updates cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/survodutide-phase3-mazdutide-nmpa-orforglipron-maintain-danuglipron-may-2026)

News & Updates [

### Survodutide Phase 3 Delivers 16.6% Weight Loss, Mazdutide Wins China Approvals, Orforglipron Maintains Injectable Weight Loss, and Pfizer Drops Danuglipron — May 2026 Peptide Research Roundup

](/blog/survodutide-phase3-mazdutide-nmpa-orforglipron-maintain-danuglipron-may-2026)

Survodutide hits 16.6% weight loss in its Phase 3 SYNCHRONIZE-1 debut, mazdutide becomes the first dual GCG/GLP-1 agonist approved anywhere with dual China NMPA approvals, orforglipron proves it can maintain injectable weight loss in ATTAIN-Maintain, Pfizer discontinues danuglipron after a liver safety signal, and the July 2026 PCAC meeting agenda takes shape.

PepTracker Pro Team 

May 2, 2026  9 min read 

survodutidemazdutideorforglipron

[Read](/blog/survodutide-phase3-mazdutide-nmpa-orforglipron-maintain-danuglipron-may-2026)

[![News & Updates cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/maritide-phase3-glp1-neurology-semaglutide-cv-outcomes-pharmacogenomics-april-2026)

News & Updates [

### MariTide Enters Phase 3, GLP-1 Neurological Repositioning Advances, Semaglutide Outperforms Tirzepatide on CV Outcomes, and GLP1R Pharmacogenomics Breakthrough: April 27, 2026

](/blog/maritide-phase3-glp1-neurology-semaglutide-cv-outcomes-pharmacogenomics-april-2026)

Amgen's once-monthly MariTide advances into phase 3 MARITIME trials with up to 20% weight loss and no plateau, GLP-1 drugs are being repositioned for Alzheimer's and Parkinson's disease, the STEER analysis finds semaglutide outperforms tirzepatide on cardiovascular outcomes, and a Nature GWAS identifies a GLP1R variant predicting individual weight loss response.

PepTracker Pro Team 

April 27, 2026  10 min read 

maritidemaridebart-cafraglutideamgen

[Read](/blog/maritide-phase3-glp1-neurology-semaglutide-cv-outcomes-pharmacogenomics-april-2026)

[![News & Updates cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/fda-category2-removal-ll37-derivatives-dihexa-primate-pps-disease-modification-april-2026)

News & Updates [

### FDA Removes 12 Peptides from Category 2, LL-37 Derivative Breakthroughs, Dihexa Primate Data, and Pentosan Polysulfate Disease-Modification Evidence: April 26, 2026

](/blog/fda-category2-removal-ll37-derivatives-dihexa-primate-pps-disease-modification-april-2026)

The FDA formally removes 12 peptides from Category 2 ahead of July PCAC hearings, LL-37 derivative research achieves improved stability and efficacy, dihexa produces measurable synaptogenesis in non-human primates, pentosan polysulfate shows 6-month disease modification in OA, and DSIP fusion peptides cross the blood-brain barrier.

PepTracker Pro Team 

April 26, 2026  9 min read 

fdacategory-2pcac

[Read](/blog/fda-category2-removal-ll37-derivatives-dihexa-primate-pps-disease-modification-april-2026)

[![News & Updates cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/amycretin-phase3-bpc157-muscle-retatrutide-weight-aacr-cancer-peptides-april-2026)

News & Updates [

### Amycretin Enters Phase 3, BPC-157 Muscle Repair Data, Retatrutide Weight Loss Confirmed, and AACR 2026 Cancer Peptide Advances: April 25, 2026

](/blog/amycretin-phase3-bpc157-muscle-retatrutide-weight-aacr-cancer-peptides-april-2026)

Novo Nordisk's amycretin enters Phase 3 for obesity with 22% weight loss from Phase 1b/2a, BPC-157 gains new muscle regeneration data ahead of July PCAC review, retatrutide's TRANSCEND-T2D-1 confirms 36.6 lbs weight loss, and AACR 2026 showcases peptide-drug conjugate breakthroughs in cancer therapy.

PepTracker Pro Team 

April 25, 2026  10 min read 

amycretinnovo-nordiskglp-1

[Read](/blog/amycretin-phase3-bpc157-muscle-retatrutide-weight-aacr-cancer-peptides-april-2026)

[![News & Updates cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/orforglipron-approved-cagrisema-reimagine2-semaglutide-alzheimers-fda-peptide-april-2026)

News & Updates [

### Orforglipron Approved, CagriSema REIMAGINE-2 Results, Semaglutide Alzheimer's Trials, and FDA Peptide Reclassification Update: April 24, 2026

](/blog/orforglipron-approved-cagrisema-reimagine2-semaglutide-alzheimers-fda-peptide-april-2026)

Eli Lilly's Foundayo (orforglipron) becomes the first oral non-peptide GLP-1 approved for weight loss, CagriSema shows superiority over semaglutide alone in REIMAGINE-2, semaglutide enters Alzheimer's Phase 3 trials, tirzepatide reduces sleep apnea events, and the FDA peptide reclassification moves forward.

PepTracker Pro Team 

April 24, 2026  12 min read 

orforglipronfoundayocagrisema

[Read](/blog/orforglipron-approved-cagrisema-reimagine2-semaglutide-alzheimers-fda-peptide-april-2026)

[![News & Updates cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/vanquish2-enrollment-glp1r-gwas-cleavenet-ai-hims-peptide-april-2026)

News & Updates [

### VANQUISH-2 Enrollment Complete, GLP1R GWAS Breakthrough, AI Peptide Design, and Hims & Hers Peptide Pivot: April 22, 2026 Update

](/blog/vanquish2-enrollment-glp1r-gwas-cleavenet-ai-hims-peptide-april-2026)

Viking Therapeutics completes VANQUISH-2 Phase 3 enrollment, a Nature GWAS identifies a GLP1R variant predicting drug response, CleaveNet AI designs tumor-targeted peptides, and Hims & Hers surges on FDA peptide review and Novo Nordisk settlement.

PepTracker Pro Team 

April 22, 2026  10 min read 

vk2735glp-1gwas

[Read](/blog/vanquish2-enrollment-glp1r-gwas-cleavenet-ai-hims-peptide-april-2026)

[![Peptide Research Updates cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/foundayo-launch-glp1-resistance-cagrisema-nejm-medicare-bridge-april-2026)

Peptide Research Updates [

### Foundayo Launches, GLP-1 Resistance Discovered, CagriSema NEJM Data, and Medicare GLP-1 Bridge: April 21, 2026 Update

](/blog/foundayo-launch-glp1-resistance-cagrisema-nejm-medicare-bridge-april-2026)

Eli Lilly's Foundayo (orforglipron) ships as the first non-peptide GLP-1 pill. Stanford discovers GLP-1 resistance in 10% of people. CagriSema REDEFINE trials published in NEJM. Medicare GLP-1 Bridge launches July 2026. FDA PCAC docket deadline updated to July 22.

PepTracker Pro Team 

April 21, 2026  11 min read 

orforglipronFoundayoGLP-1

[Read](/blog/foundayo-launch-glp1-resistance-cagrisema-nejm-medicare-bridge-april-2026)

[![Peptide Research Updates cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/wegovy-hd-retatrutide-phase3-eloralintide-amylin-april-2026)

Peptide Research Updates [

### Wegovy HD Launches, Retatrutide Phase 3 Triumphs, and Eloralintide Opens a New Drug Class: April 20, 2026 Update

](/blog/wegovy-hd-retatrutide-phase3-eloralintide-amylin-april-2026)

Semaglutide 7.2 mg (Wegovy HD) launches with 20.7% weight loss data. Retatrutide Phase 3 delivers 28.7% loss plus osteoarthritis relief. Eloralintide introduces a new amylin-based drug class. VK2735 oral dual agonist enters Phase 3 despite tolerability questions.

PepTracker Pro Team 

April 20, 2026  12 min read 

semaglutideWegovy-HD7.2mg

[Read](/blog/wegovy-hd-retatrutide-phase3-eloralintide-amylin-april-2026)

[![Peptide Research Updates cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/brp-peptide-monthly-glp1-obesity-pipeline-april-2026)

Peptide Research Updates [

### Stanford's BRP Peptide, Monthly GLP-1 Shots, and the Expanding Obesity Pipeline: April 2026 Peptide Update

](/blog/brp-peptide-monthly-glp1-obesity-pipeline-april-2026)

A Stanford AI tool discovers BRP — a natural appetite peptide without GLP-1 side effects. Pfizer's monthly GLP-1 shot enters Phase 3 planning. Pemvidutide earns Breakthrough Therapy status for MASH. Oral Wegovy launches. The obesity peptide pipeline is expanding faster than ever.

PepTracker Pro Team 

April 19, 2026  14 min read 

BRPGLP-1obesity

[Read](/blog/brp-peptide-monthly-glp1-obesity-pipeline-april-2026)

[![Research Summaries cover image](/assets/blog-research-summaries-wT5DEY1k.jpg)](/blog/peptide-research-2026-key-developments)

Research Summaries [

### Peptide Research in 2026: Key Developments, FDA Changes, and Emerging Compounds

](/blog/peptide-research-2026-key-developments)

A comprehensive look at the biggest peptide developments of 2026 so far — from FDA approvals and reclassifications to breakthrough clinical trial results and the rise of longevity peptides.

PepTracker Pro Team 

April 18, 2026  14 min read 

2026FDAGLP-1

[Read](/blog/peptide-research-2026-key-developments)

[![Research Summaries cover image](/assets/blog-research-summaries-wT5DEY1k.jpg)](/blog/ghk-cu-breakout-2026)

Research Summaries [

### GHK-Cu: The Breakout Peptide of 2026

](/blog/ghk-cu-breakout-2026)

With search interest up over 1,000% year-over-year, GHK-Cu has emerged as the most talked-about peptide of 2026. Here's why the science backs up the hype.

PepTracker Pro Team 

March 15, 2026  11 min read 

ghk-cucopper-peptideskin

[Read](/blog/ghk-cu-breakout-2026)

[![Research Summaries cover image](/assets/blog-research-summaries-wT5DEY1k.jpg)](/blog/fda-peptide-reclassification-2026)

Research Summaries [

### FDA Peptide Reclassification 2026: What Changed and What It Means

](/blog/fda-peptide-reclassification-2026)

In February 2026, the FDA reclassified 14 peptides back to Category 1 compounding status. Here's what this means for researchers, clinicians, and patients.

PepTracker Pro Team 

March 1, 2026  12 min read 

fdaregulationcompounding

[Read](/blog/fda-peptide-reclassification-2026)

[![Research Summaries cover image](/assets/blog-research-summaries-wT5DEY1k.jpg)](/blog/mitochondrial-peptides-science)

Research Summaries [

### Mitochondrial Peptides: MOTS-c, SS-31, NAD+, and the Science of Cellular Energy

](/blog/mitochondrial-peptides-science)

A deep dive into mitochondrial-targeted peptides and molecules — how they work, what research shows, and why cellular energy is central to aging science.

PepTracker Pro Team 

February 10, 2026  16 min read 

mots-css-31nad

[Read](/blog/mitochondrial-peptides-science)

[![Peptide Guides cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/fertility-peptides-overview)

Peptide Guides [

### Fertility Peptides: HCG, HMG, and Kisspeptin Research

](/blog/fertility-peptides-overview)

An overview of peptides and hormones used in fertility medicine — from established treatments to emerging research compounds.

PepTracker Pro Team 

February 1, 2026  15 min read 

fertilityhcghmg

[Read](/blog/fertility-peptides-overview)

[![Research Summaries cover image](/assets/blog-research-summaries-wT5DEY1k.jpg)](/blog/tanning-peptides-melanocortin)

Research Summaries [

### Tanning Peptides: MT-1, MT-2, and the Melanocortin System

](/blog/tanning-peptides-melanocortin)

An educational look at melanocortin-based tanning peptides — how they work, their regulatory status, and important safety considerations.

PepTracker Pro Team 

January 20, 2026  14 min read 

mt-1mt-2pigmentation

[Read](/blog/tanning-peptides-melanocortin)

[![Peptide Guides cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/glp-1-peptides-explained)

Peptide Guides [

### GLP-1 Peptides Explained: Semaglutide, Tirzepatide, and Beyond

](/blog/glp-1-peptides-explained)

A comprehensive guide to GLP-1 receptor agonists — how they work, what sets them apart, and where the science is heading.

PepTracker Pro Team 

January 15, 2026  16 min read 

glp-1semaglutidetirzepatide

[Read](/blog/glp-1-peptides-explained)

[![Research Summaries cover image](/assets/blog-research-summaries-wT5DEY1k.jpg)](/blog/immune-peptides-overview)

Research Summaries [

### Immune-Modulating Peptides: Thymosin Alpha-1 and Beyond

](/blog/immune-peptides-overview)

An overview of peptides studied for immune system modulation, from approved medications to emerging research.

PepTracker Pro Team 

December 10, 2025  14 min read 

immunethymosin-alpha-1selank

[Read](/blog/immune-peptides-overview)

[![Research Summaries cover image](/assets/blog-research-summaries-wT5DEY1k.jpg)](/blog/ghk-cu-skin-science)

Research Summaries [

### Skin and Anti-Aging Peptides: The Science Behind GHK-Cu

](/blog/ghk-cu-skin-science)

An evidence-based look at GHK-Cu, one of the most researched peptides in dermatology and anti-aging science.

PepTracker Pro Team 

December 1, 2025  15 min read 

ghk-cuskinanti-aging

[Read](/blog/ghk-cu-skin-science)

[![Glossary Highlights cover image](/assets/blog-glossary-highlights-nQG4tpmG.jpg)](/blog/understanding-bioavailability)

Glossary Highlights [

### Glossary Spotlight: Understanding Bioavailability

](/blog/understanding-bioavailability)

A deep dive into bioavailability — why it matters for peptides and how it affects research outcomes.

PepTracker Pro Team 

November 25, 2025  13 min read 

bioavailabilitypharmacokineticsbasics

[Read](/blog/understanding-bioavailability)

[![Research Summaries cover image](/assets/blog-research-summaries-wT5DEY1k.jpg)](/blog/sleep-peptides-science)

Research Summaries [

### The Science of Sleep Peptides

](/blog/sleep-peptides-science)

Exploring what research says about peptides studied for sleep regulation, including DSIP and others.

PepTracker Pro Team 

November 20, 2025  13 min read 

sleepdsipresearch

[Read](/blog/sleep-peptides-science)

[![Peptide Guides cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/gh-peptides-explained)

Peptide Guides [

### Growth Hormone Peptides: CJC-1295 and Ipamorelin Explained

](/blog/gh-peptides-explained)

An educational overview of growth hormone secretagogues, how they work, and what research has found.

PepTracker Pro Team 

November 15, 2025  14 min read 

growth-hormonecjc-1295ipamorelin

[Read](/blog/gh-peptides-explained)

[![Myth vs Fact cover image](/assets/blog-myth-vs-fact-hmyEbTPC.jpg)](/blog/myth-vs-fact-peptides)

Myth vs Fact [

### Myth vs Fact: Common Peptide Misconceptions

](/blog/myth-vs-fact-peptides)

Separating science from hype — addressing the most common misconceptions about peptides.

PepTracker Pro Team 

November 10, 2025  13 min read 

mythsfactseducation

[Read](/blog/myth-vs-fact-peptides)

[![Peptide Guides cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/bpc-157-vs-tb-500)

Peptide Guides [

### BPC-157 vs TB-500: Comparing Recovery Peptides

](/blog/bpc-157-vs-tb-500)

A side-by-side comparison of two popular recovery peptides, examining what research says about each.

PepTracker Pro Team 

November 1, 2025  15 min read 

bpc-157tb-500recovery

[Read](/blog/bpc-157-vs-tb-500)

[![Peptide Guides cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/peptide-safety-basics)

Peptide Guides [

### Peptide Safety: What You Need to Know

](/blog/peptide-safety-basics)

A high-level overview of safety considerations when researching peptides, including quality indicators and red flags.

PepTracker Pro Team 

October 20, 2025  14 min read 

safetycautionsquality

[Read](/blog/peptide-safety-basics)

[![Research Summaries cover image](/assets/blog-research-summaries-wT5DEY1k.jpg)](/blog/evidence-levels-explained)

Research Summaries [

### Understanding Evidence Levels in Peptide Research

](/blog/evidence-levels-explained)

What does 'low,' 'medium,' or 'high' evidence mean? Learn how to interpret research quality when evaluating peptides.

PepTracker Pro Team 

October 15, 2025  13 min read 

researchevidenceclinical-trials

[Read](/blog/evidence-levels-explained)

[![Peptide Guides cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/what-are-peptides)

Peptide Guides [

### What Are Peptides? A Beginner's Guide

](/blog/what-are-peptides)

An accessible introduction to peptides — what they are, how they differ from proteins, and why researchers are interested in them.

PepTracker Pro Team 

October 1, 2025  12 min read 

basicspeptidesamino-acids

[Read](/blog/what-are-peptides)

Track Your Research with PepTracker Pro

[Try the Free App →](https://app.peptrackerpro.com)

[PepTracker Pro](/)

Educational peptide information and research tracking tools. Not medical advice.

#### Explore

-   [Peptide Directory](/peptides)
-   [Compare Peptides](/compare)
-   [Glossary](/glossary)
-   [Benefits](/benefits/sleep)

#### Learn

-   [Blog](/blog)
-   [Calculators](/calculators)
-   [Start Here](/start)
-   [About](/about)

#### Legal

-   [Editorial Policy](/editorial-policy)
-   [Research Disclaimer](/research-disclaimer)
-   [Disclaimer](/disclaimer)
-   [Privacy Policy](/privacy)
-   [Terms of Service](/terms)
-   [Contact](/contact)

© 2026 PepTracker Pro. Educational purposes only. Not medical advice. Always consult a licensed healthcare provider.